<SEC-DOCUMENT>0001811884-24-000015.txt : 20240510
<SEC-HEADER>0001811884-24-000015.hdr.sgml : 20240510
<ACCEPTANCE-DATETIME>20240510111846
ACCESSION NUMBER:		0001811884-24-000015
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240510
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		24933485

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20240331.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://www.utahmed.com/20240331" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="Y24Q1" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="Y24Q1" id="fact2">--12-31</ix:nonNumeric>
<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="Y24Q1" id="fact3">Yes</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="Y24Q1" id="fact4">false</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="Y24Q1" id="fact5">2024</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="Y24Q1" id="fact6">Q1</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20240331.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:unit id="USD">
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id="Shares">
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id="UsdPerShare">
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
<i:unit id="Pure">
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:context id="Y24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E24Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="I240509">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2024-05-09</i:instant>
</i:period>
</i:context>
<i:context id="E23">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y23Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E22">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E23_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E23_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E24Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2024-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="E22_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y23Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-CommonStock">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-AddPaidInCap">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-ComprIncome">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="E23Q1_StEqComps-RetainedEarnings">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id="Y24Q1_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-Obstetrics">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-Obstetrics_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-Obstetrics_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-Neonatal">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-Neonatal_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-Neonatal_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2024-01-01</i:startDate>
<i:endDate>2024-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-03-31</i:endDate>
</i:period>
</i:context>
<i:context id="D240401_240503">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2024-04-01</i:startDate>
<i:endDate>2024-05-03</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">UNITED STATES</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Washington, D.C. &#160;20549</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">FORM<b> </b><ix:nonNumeric name="dei:DocumentType" contextRef="Y24Q1" escape="true" id="ixv-4094">10-Q</ix:nonNumeric></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><span style="font-family:MS Gothic"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="Y24Q1" format="ixt-sec:boolballotbox" id="ixv-4095">&#9746;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="Y24Q1" format="ixt:date-monthname-day-year-en" id="ixv-4096">March 31, 2024</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">OR</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0"><span style="font-family:MS Gothic"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="Y24Q1" format="ixt-sec:boolballotbox" id="ixv-4097">&#9744;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">For the transition period from  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Commission File No. <span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="Y24Q1" escape="true" id="ixv-4098">001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="Y24Q1" escape="true" id="ixv-4099">UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(Exact name of Registrant as specified in its charter)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="Y24Q1" format="ixt-sec:stateprovnameen" id="ixv-4100">Utah</ix:nonNumeric></span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="Y24Q1" escape="true" id="ixv-4101">87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of incorporation or organization)</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="Y24Q1" escape="true" id="ixv-4102">7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="Y24Q1" escape="true" id="ixv-4103">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="Y24Q1" format="ixt-sec:stateprovnameen" id="ixv-4104">Utah</ix:nonNumeric> &#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="Y24Q1" escape="true" id="ixv-4105">84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="Y24Q1" escape="true" id="ixv-4106">801</ix:nonNumeric>) </span><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="Y24Q1" escape="true" id="ixv-4107">566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign="top" style="width:100%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Title of each class:</p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Trading Symbol:</p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="Y24Q1" escape="true" id="ixv-4108">Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign="top" style="width:33.34%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="Y24Q1" escape="true" id="ixv-4109">UTMD</ix:nonNumeric></p>
</td><td valign="top" style="width:33.32%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="Y24Q1" id="ixv-4110">NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<span style="-sec-ix-hidden:fact3">Yes</span>&#160;<span style="font-family:MS Gothic">&#9746;</span> &#160;&#160;No&#160;<span style="font-family:MS Gothic">&#9744;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="Y24Q1" id="ixv-4111">Yes</ix:nonNumeric>&#160;<span style="font-family:MS Gothic">&#9746;</span> &#160;&#160;No&#160;<span style="font-family:MS Gothic">&#9744;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Large accelerated filer&#160;<span style="font-family:MS Gothic">&#9744;</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Accelerated filer&#160;<span style="font-family:MS Gothic">&#9744;</span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="Y24Q1" format="ixt-sec:entityfilercategoryen" id="ixv-4112">Non-accelerated filer</ix:nonNumeric> <span style="font-family:MS Gothic">&#9746;</span></p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Smaller reporting company <span style="font-family:MS Gothic"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="Y24Q1" format="ixt-sec:boolballotbox" id="ixv-4113">&#9746;</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:50%"><p style="font:10pt Times New Roman;margin:0">Emerging growth company <span style="font-family:MS Gothic"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="Y24Q1" format="ixt-sec:boolballotbox" id="ixv-4114">&#9744;</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:MS Gothic">&#9744;</span> &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<span style="font-family:MS Gothic"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="Y24Q1" format="ixt-sec:boolballotbox" id="ixv-4115">&#9744;</ix:nonNumeric></span> &#160;&#160;No&#160;<span style="font-family:MS Gothic">&#9746;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:18pt"></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of May 9, 2024: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="I240509" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-4116">3,528,426</ix:nonFraction>.&#160;</p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a2"></a><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">INDEX TO FORM 10-Q</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">PAGE</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">PART I - FINANCIAL INFORMATION</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Item 1.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a4" style="text-decoration:none">Financial Statements</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a5" style="text-decoration:none">Consolidated Condensed Balance Sheets as of March 31, 2024 and December 31, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a6" style="text-decoration:none">Consolidated Condensed Statements of Income for the three months ended March 31, 2024 and March 31, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">2</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a7" style="text-decoration:none">Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2024 and March 31, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">3</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a8" style="text-decoration:none">Consolidated Condensed Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and March 31, 2023</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">4</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a9" style="text-decoration:none">Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">5</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Item 2.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:42.3pt"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a10" style="text-decoration:none">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">7</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Item 3.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a11" style="text-decoration:none">Quantitative and Qualitative Disclosures About Market Risk</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">14</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Item 4.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a12" style="text-decoration:none">Controls and Procedures</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">14</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a13" style="text-decoration:none">PART II &#8211;&#160;OTHER INFORMATION</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">Item 1.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a14" style="text-decoration:none">Legal Proceedings</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a15" style="text-decoration:none">Item 1A.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a15" style="text-decoration:none">Risk Factors</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a16" style="text-decoration:none">Item 2.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a16" style="text-decoration:none">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">15</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a17" style="text-decoration:none">Item 6.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a17" style="text-decoration:none">Exhibits</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">16</p>
</td></tr>
<tr><td valign="top" style="width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:19.12%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a18" style="text-decoration:none">SIGNATURES</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:68.14%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.72%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">17</p>
</td></tr>
</table>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a4"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">PART I - FINANCIAL INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>Item 1. Financial Statements</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a5"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">MARCH 31, 2024 AND DECEMBER 31, 2023</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(unaudited)</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(audited)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"/><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">MARCH 31, 2024</span></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">DECEMBER 31, 2023</span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><span style="border-bottom:1px solid #000000">ASSETS</span></p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0">Current assets:</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Cash &amp; Investments</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$  &#160;&#160;&#160;<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4117">93,808</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4118">92,868</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts &amp; other receivables, net</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4119">3,591</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4120">3,391</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Inventories</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4121">9,240</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4122">9,582</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Other current assets</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4123">510</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4124">428</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total current assets</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4125">107,149</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4126">106,269</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0">Property and equipment, net</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4127">10,266</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4128">10,551</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Goodwill</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4129">13,638</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4130">13,692</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Other intangible assets</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4131">54,029</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4132">54,296</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Other intangible assets - accumulated amortization</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4133">49,641</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4134">49,350</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0">Other intangible assets, net</p>
</td><td valign="bottom" style="width:315.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4135">4,388</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4136">4,946</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total assets</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:Assets" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4137">135,441</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:Assets" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4138">135,458</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><span style="border-bottom:1px solid #000000">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0">Current liabilities:</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts payable</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4139">998</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4140">769</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accrued expenses</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4141">4,476</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4142">3,941</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total current liabilities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4143">5,474</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4144">4,710</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Deferred tax liability &#8211; Femcare IIA</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4145">986</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4146">1,120</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Other long term liabilities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4147">698</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4148">698</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Long-term lease liability</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4149">285</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4150">295</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0">Deferred income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4151">256</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4152">322</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total liabilities</p>
</td><td valign="bottom" style="width:315.1pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4153">7,699</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4154">7,145</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0">Stockholders' equity:</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Common stock - $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4155"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="E23" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4156">0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4157"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="E23" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4158">50,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - March 31, 2024, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4159"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4160">3,588</ix:nonFraction></ix:nonFraction> shares and December 31, 2023, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="E23" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4161"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="E23" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4162">3,628</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4163">36</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4164">36</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accumulated other comprehensive loss</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4165">11,289</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" contextRef="E23" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4166">10,658</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Additional paid-in capital</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4167">0</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4168">594</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Retained earnings</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4169">138,995</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4170">138,341</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total stockholders' equity</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4171">127,742</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4172">128,313</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.1pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total liabilities and stockholders' equity</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.1pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4173">135,441</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315.15pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;<ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4174">135,458</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:8pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:315.1pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.1pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:315.1pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315.15pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">1</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a6"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">THREE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="4" valign="bottom" style="width:1412.25pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:665.1pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">THREE MONTHS ENDED</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">MARCH 31,</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"/><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Sales, net</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4175">11,340</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4176">12,520</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Cost of goods sold</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4177">4,574</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4178">4,677</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Gross profit</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4179">6,766</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4180">7,843</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Operating expense</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Selling, general and administrative</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4181">2,617</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4182">3,260</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Research &amp; development</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4183">266</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4184">144</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total operating expenses</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4185">2,883</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4186">3,404</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating income</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4187">3,883</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4188">4,439</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other income</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4189">915</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4190">680</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Income before provision for income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4191">4,798</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4192">5,119</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Provision for income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4193">842</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4194">905</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net income</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4195">3,956</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4196">4,214</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (basic)</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4197">1.09</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4198">1.16</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per common share (diluted)</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4199">1.09</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4200">1.16</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding (basic)</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4201">3,618</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y23Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4202">3,628</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Shares outstanding (diluted)</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4203">3,618</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y23Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4204">3,636</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other comprehensive income (loss):</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Foreign currency translation net of taxes of $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4205"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y23Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4206"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y24Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4207"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="Y23Q1" decimals="INF" unitRef="USD" scale="0" format="ixt:num-dot-decimal" id="ixv-4208">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160; &#160;(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4209">631</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160; &#160;<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4210">549</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total comprehensive income</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4211">3,325</ix:nonFraction></p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4212">4,763</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;margin-left:38.9pt">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:747.15pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:35.1pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:315pt;padding-left:5.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">2</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a7"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td colspan="5" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="5" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="5" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="5" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands - unaudited)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:378.15pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">THREE MONTHS ENDED</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">MARCH 31,</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"/><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:179.9pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:163.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4213">3,956</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4214">4,214</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities:</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Depreciation</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4215">156</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4216">155</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Amortization</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4217">513</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4218">1,596</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt CG Times;margin:0;margin-left:10.1pt"><span style="font-family:Times New Roman">Provision for losses on/(recovery of) accounts receivable</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt CG Times;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4219">8</ix:nonFraction>)</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4220">1</ix:nonFraction></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Amortization of right-of-use assets</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4221">14</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4222">13</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt CG Times;margin:0;margin-left:10.1pt"><span style="font-family:Times New Roman">Deferred income taxes</span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4223">192</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="Y23Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4224">3</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Stock-based compensation expense</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4225">79</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4226">50</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Tax benefit attributable to exercise of stock options</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4227">9</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4228">2</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Changes in operating assets and liabilities:</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts receivable and other receivables</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4229">214</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="Y23Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4230">1,789</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Inventories</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4231">271</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4232">1,084</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Prepaid expenses and other current assets</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4233">87</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Y23Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4234">25</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accounts payable</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4235">230</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="Y23Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4236">193</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:20.9pt">Accrued expenses</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4237">549</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4238">350</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Total adjustments</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4239">1,320</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4240">2,701</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net cash provided by operating activities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt;border-top:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4241">5,276</ix:nonFraction></span></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt;border-top:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4242">6,915</ix:nonFraction></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Capital expenditures for:</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Property and equipment</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4243">22</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4244">43</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from sale of equipment</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4245">27</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="Y23Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4246">-</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net cash provided by/(used in) investing activities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4247">5</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Y23Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4248">43</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Proceeds from issuance of common stock - options</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4249">96</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4250">21</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Common stock purchased and retired</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4251">2,990</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="Y23Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4252">-</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Payment of dividends</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4253">1,089</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4254">1,070</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:38.9pt">Net cash used in financing activities</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4255">3,983</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Y23Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4256">1,049</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Effect of exchange rate changes on cash</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4257">358</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4258">37</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Net increase in cash and cash equivalents</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4259">940</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4260">5,860</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Cash at beginning of period</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4261">92,868</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E22" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4262">75,052</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">Cash at end of period</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4263">93,808</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="E23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4264">80,912</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="background-color:#CCEEFF;width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Cash paid during the period for income taxes</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4265">105</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4266">129</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt Times New Roman;margin:0;margin-left:10.1pt">Cash paid during the period for interest</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="Y24Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4267">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="Y23Q1" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4268">-</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:10pt CG Times;margin:0;margin-left:10.1pt">&#160;</p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:961.8pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="bottom" style="width:72.3pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="bottom" style="width:179.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:34.95pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:163.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">3</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a8"></a><p style="font:10pt CG Times;margin:0"></p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td colspan="12" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="12" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="12" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">THREE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023</span></p>
</td></tr>
<tr style="height:11.5pt"><td colspan="12" valign="bottom" style="width:1412.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(in thousands - unaudited)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Accumulated</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Additional</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Other</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="bottom" style="width:263.15pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Common Stock</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Paid-in</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Comprehensive</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Retained</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Stockholders'</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:345.35pt"/><td valign="bottom" style="width:113.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Shares</p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:121pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Amount</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:150.8pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Capital</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Income</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Earnings</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Equity</p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Balance at December 31, 2023</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:113.65pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4269">3,630</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:121pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4270">36</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:150.8pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4271">593</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:199.4pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4272">10,658</ix:nonFraction>)</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:158.3pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4273">138,341</ix:nonFraction></p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:180.65pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4274">128,313</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Shares issued upon exercise of employee stock options for cash</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4275">2</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4276">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4277">96</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4278">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4279">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4280">96</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Stock option compensation expense</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4281">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4282">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4283">79</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4284">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4285">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4286">79</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Common stock purchased and retired</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4287">43</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4288">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4289">769</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4290">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4291">2,221</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4292">2,990</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Foreign currency translation adjustment</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4293">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4294">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4295">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4296">631</ix:nonFraction>)</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4297">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="color:#FF0000"> </span>(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4298">631</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Common stock dividends</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4299">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4300">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4301">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4302">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4303">1,081</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4304">1,081</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Net income</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:113.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4305">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:121pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4306">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:150.8pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4307">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:199.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4308">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:158.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4309">3,956</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:180.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4310">3,956</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Balance at March 31, 2024</p>
</td><td valign="middle" style="width:113.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4311">3,588</ix:nonFraction></p>
</td><td valign="middle" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:121pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4312">36</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:150.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4313">-</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:199.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4314">11,289</ix:nonFraction>)</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:158.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4315">138,995</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:180.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4316">127,742</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt CG Times;margin:0">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:113.65pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:121pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:150.8pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:199.4pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:158.3pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:180.65pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Balance at December 31, 2022</p>
</td><td valign="middle" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E22_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4317">3,628</ix:nonFraction></p>
</td><td valign="middle" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E22_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4318">36</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E22_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4319">251</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E22_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4320">12,039</ix:nonFraction>)</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E22_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4321">126,006</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E22" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4322">114,254</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Shares issued upon exercise of employee stock options for cash</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-4323">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4324">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4325">21</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4326">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4327">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4328">21</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Stock option compensation expense</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4329">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4330">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4331">50</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4332">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4333">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4334">50</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Foreign currency translation adjustment</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4335">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4336">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4337">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4338">549</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4339">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"> <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4340">549</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Common stock dividends</p>
</td><td valign="bottom" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4341">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4342">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4343">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4344">-</ix:nonFraction></p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4345">1,070</ix:nonFraction>)</p>
</td><td valign="bottom" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<ix:nonFraction name="us-gaap:DividendsCommonStockCash" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4346">1,070</ix:nonFraction>)</p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="background-color:#CCEEFF;width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Net income</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:113.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4347">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:121pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4348">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:150.8pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4349">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:199.4pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" format="ixt:fixed-zero" id="ixv-4350">-</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:158.3pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4351">4,214</ix:nonFraction></p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="bottom" style="background-color:#CCEEFF;width:180.65pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4352">4,214</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt Times New Roman;margin:0"> Balance at March 31, 2023</p>
</td><td valign="middle" style="width:113.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="E23Q1_StEqComps-CommonStock" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4353">3,628</ix:nonFraction></p>
</td><td valign="middle" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:121pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23Q1_StEqComps-CommonStock" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4354">36</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:150.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23Q1_StEqComps-AddPaidInCap" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4355">322</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:199.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23Q1_StEqComps-ComprIncome" decimals="-3" unitRef="USD" sign="-" scale="3" format="ixt:num-dot-decimal" id="ixv-4356">11,491</ix:nonFraction>)</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:158.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23Q1_StEqComps-RetainedEarnings" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4357">129,150</ix:nonFraction></p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:180.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="E23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4358">118,018</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="middle" style="width:345.35pt"><p style="font:10pt CG Times;margin:0">&#160;</p>
</td><td valign="middle" style="width:113.65pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:121pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:150.8pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:199.4pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:158.3pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:180.65pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="bottom" style="width:345.35pt"><p style="font:8pt Times New Roman;margin:0"><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign="middle" style="width:113.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:121pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:150.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:199.4pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:158.3pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:28.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:180.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">4</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a9"></a><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">(unaudited)</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2223"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2023. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style="font:10pt CG Times;margin:0">&#160;</p>
 <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2226"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2229"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
</ix:nonNumeric></ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2232"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at March 31, 2024 and December 31, 2023 consisted of the following:</p>
<ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2234"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top" style="width:421.4pt"/><td valign="top" style="width:19pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:316pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center"> March 31, 2024  </p>
</td><td valign="top" style="width:24.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:19pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:295.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2023</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:421.4pt"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td valign="top" style="background-color:#CCEEFF;width:19pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:316pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4359">1,634</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:24.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:19pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="background-color:#CCEEFF;width:295.5pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4360">1,685</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:421.4pt"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top" style="width:19pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:316pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4361">1,302</ix:nonFraction></p>
</td><td valign="top" style="width:24.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:19pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:295.5pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4362">1,503</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:421.4pt"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td valign="top" style="background-color:#CCEEFF;width:19pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:316pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4363">6,304</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:24.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:19pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:295.5pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4364">6,394</ix:nonFraction></p>
</td></tr>
<tr><td valign="top" style="width:421.4pt"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:19pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="width:316pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4365">9,240</ix:nonFraction></p>
</td><td valign="top" style="width:24.85pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:19pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td valign="top" style="width:295.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="E23" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4366">9,582</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2301"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At March 31, 2024, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2024 and March 31, 2023, the Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4367">79</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4368">50</ix:nonFraction>, respectively, in stock-based compensation cost.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ProductWarrantyDisclosureTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2305"><p style="font:10pt Times New Roman;margin:0"> (5) Warranty Reserve. &#160;&#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, <ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="E23" decimals="INF" unitRef="USD" format="ixt:fixed-zero" id="ixv-4369"><ix:nonFraction name="us-gaap:ProductWarrantyAccrual" contextRef="E24Q1" decimals="INF" unitRef="USD" format="ixt:fixed-zero" id="ixv-4370">no</ix:nonFraction></ix:nonFraction> warranty reserve was made at December 31, 2023 or March 31, 2024. </p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
 <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2309"><p style="font:10pt Times New Roman;margin:0">(6) &#160;1Q 2024 global revenues (USD) by product category:</p>
<ix:nonNumeric name="fil:ScheduleOfRevenuesByProductCategoryTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2311"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="top" style="width:180pt"/><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-Obstetrics_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4371">803</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-Obstetrics_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4372">222</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-Obstetrics" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4373">1,025</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4374">2,353</ix:nonFraction></span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4375">3,108</ix:nonFraction></span></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4376">5,461</ix:nonFraction></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-Neonatal_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4377">1,247</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-Neonatal_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4378">395</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-Neonatal" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4379">1,642</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:180pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4380">1,788</ix:nonFraction></span></p>
</td><td valign="top" style="width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4381">1,424</ix:nonFraction></span></p>
</td><td valign="top" style="width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:54pt;border-bottom:0.5pt solid #000000"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4382">3,212</ix:nonFraction></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:180pt"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_StGeo-DomesticUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4383">6,191</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:23.05pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1_StGeo-OutsideUs" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4384">5,149</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:28.1pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:8.65pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4385">11,340</ix:nonFraction></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style="font:12pt Times New Roman;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">5</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2462"><p style="font:10pt Times New Roman;margin:0">(7) Exclusive U.S. Filshie Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution and use of intellectual property rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) effective February 1, 2019. The $<ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4386">21,000</ix:nonFraction> purchase price represented an identifiable intangible asset which was straight-line amortized and recognized as part of G&amp;A expenses over the <ix:nonFraction name="fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem" contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc" decimals="INF" unitRef="Pure" scale="0" format="ixt:num-dot-decimal" id="ixv-4387">4.75</ix:nonFraction> year remaining life of the CSI Agreement with Femcare ended in October 2023.</p>
</ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2465"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period. &#160;Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2024 and 2023, as applicable.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2468"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" valign="top" style="width:560.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" valign="top" style="width:560.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"/><td valign="middle" style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td valign="top" style="width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="middle" style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td valign="middle" style="width:228.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y24Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4388">3,956</ix:nonFraction></p>
</td><td valign="top" style="width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:267.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="Y23Q1" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4389">4,214</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td valign="top" style="width:228.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:267.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4390">3,618</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="Y23Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4391">3,628</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td valign="middle" style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y24Q1" decimals="-3" unitRef="Shares" format="ixt:fixed-zero" id="ixv-4392">-</ix:nonFraction></p>
</td><td valign="top" style="width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="Y23Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4393">8</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y24Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4394">3,618</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Y23Q1" decimals="-3" unitRef="Shares" scale="3" format="ixt:num-dot-decimal" id="ixv-4395">3,636</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="middle" style="width:228.2pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:267.65pt;padding-right:5.75pt;border-top:3px double #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ <ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4396">1.09</ix:nonFraction></p>
</td><td valign="top" style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ <ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4397">1.16</ix:nonFraction></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:535.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td valign="middle" style="width:228.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ <ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y24Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4398">1.09</ix:nonFraction></p>
</td><td valign="top" style="width:64.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="middle" style="width:267.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ <ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4399">1.16</ix:nonFraction></p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style="font:10pt Times New Roman;margin:0">&#160;</p>
<ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="Y24Q1" escape="true" id="ixv-2586"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2024 financial statements. &#160;After March 31, 2024 through May 3, 2024, the Company made additional repurchases of <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="D240401_240503" decimals="INF" unitRef="Shares" scale="0" format="ixt:num-dot-decimal" id="ixv-4400">63,985</ix:nonFraction> shares of its stock in the open market for $<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D240401_240503" decimals="-3" unitRef="USD" scale="3" format="ixt:num-dot-decimal" id="ixv-4401">4,323</ix:nonFraction>, at an average price of $<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" contextRef="D240401_240503" decimals="INF" unitRef="UsdPerShare" scale="0" format="ixt:num-dot-decimal" id="ixv-4402">67.57</ix:nonFraction> per share.</p>
</ix:nonNumeric><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">6</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a10"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">General</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2023 provided a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &#160;Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&#160;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Analysis of Results of Operations</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">a)</kbd><kbd style="margin-left:24.3pt"></kbd>Overview&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income statement results in the first quarter (1Q) of 2024 compared to 1Q 2023 were as follows::</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2023</span></p>
</td><td valign="top" style="width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net Sales</p>
</td><td valign="top" style="background-color:#CCEEFF;width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 11,340</p>
</td><td valign="top" style="background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 12,520</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(9.4%)</p>
</td></tr>
<tr><td valign="top" style="width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gross Profit</p>
</td><td valign="top" style="width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,766</p>
</td><td valign="top" style="width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,843</p>
</td><td valign="top" style="width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(13.7%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Operating Income</p>
</td><td valign="top" style="background-color:#CCEEFF;width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,883</p>
</td><td valign="top" style="background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,439</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(12.5%)</p>
</td></tr>
<tr><td valign="top" style="width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Income Before Tax</p>
</td><td valign="top" style="width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,798</p>
</td><td valign="top" style="width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,119</p>
</td><td valign="top" style="width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(6.3%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Net Income </p>
</td><td valign="top" style="background-color:#CCEEFF;width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td><td valign="top" style="background-color:#CCEEFF;width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,214</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(6.1%)</p>
</td></tr>
<tr><td valign="top" style="width:345.35pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Earnings per Share (diluted)</p>
</td><td valign="top" style="width:125.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.093</p>
</td><td valign="top" style="width:115.15pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.159</p>
</td><td valign="top" style="width:104.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">(5.7%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Profit margins in 1Q 2024 compared to 1Q 2023 follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:448.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt">&#160;</p>
</td><td valign="top" style="width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">1Q 2024 </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(JAN &#8211;&#160;MAR)</span></p>
</td><td valign="top" style="width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">1Q 2023 </p>
<p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">(JAN &#8211;&#160;MAR)</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:448.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Gross Profit Margin (Gross Profit/ sales):</p>
</td><td valign="top" style="background-color:#CCEEFF;width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">59.7%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">62.6%</p>
</td></tr>
<tr><td valign="top" style="width:448.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Operating Income Margin (Operating Income/ sales):</p>
</td><td valign="top" style="width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">34.2%</p>
</td><td valign="top" style="width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">35.5%</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:448.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">EBT Margin (Profits before Income Taxes/ sales):</p>
</td><td valign="top" style="background-color:#CCEEFF;width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">42.3%</p>
</td><td valign="top" style="background-color:#CCEEFF;width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">40.9%</p>
</td></tr>
<tr><td valign="top" style="width:448.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">Net Income Margin (Profit after Taxes/ sales):</p>
</td><td valign="top" style="width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">34.9%</p>
</td><td valign="top" style="width:121pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">33.7%</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic sales in 1Q 2024 were 14% lower and sales outside the U.S. (OUS) were 3% lower, in USD terms, compared to 1Q 2023. &#160;Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales were 4% lower. Although 31% of consolidated USD sales were invoiced in foreign currencies, the change in FX rates for OUS sales had a minor impact on period-to-period relative financial results. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2024 and 1Q 2023 follow: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">1Q 2023</span></p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.267</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.215</p>
</td><td valign="top" style="background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">4.3%</p>
</td></tr>
<tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.083</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.078</p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">0.4%</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.658</p>
</td><td valign="top" style="background-color:#CCEEFF;width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.685</p>
</td><td valign="top" style="background-color:#CCEEFF;width:175.3pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">(4.1%)</span></p>
</td></tr>
<tr><td valign="top" style="width:171.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.742</p>
</td><td valign="top" style="width:171.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.739</p>
</td><td valign="top" style="width:175.3pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">0.4%</span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The weighted-average positive impact on foreign currency sales was 1.2%, increasing reported USD sales $40 relative to the same foreign currency sales in 1Q 2023. &#160;In constant currency terms, total consolidated 1Q 2024 sales were $1,220 (9.7%) lower than in 1Q 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s 1Q 2024 Gross Profit at $6,766 was $1,077 lower than 1Q 2023 Gross Profit of $7,843. &#160;The 13.7% lower Gross Profit was the result of 9.4% lower sales combined with a Gross Profit Margin (GPM), Gross Profit/revenues, almost three percentage points lower than in 1Q 2023. The lower GPM was due to manufacturing overhead costs which did not decline proportionately to the sales decline. However, the decline in GPM was less than expected due to a favorable product mix and improved direct labor productivity.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated Operating Income, which is Gross Profit less Operating Expense, in 1Q 2024 at $3,883 (34.2% of sales) was $556 lower than 1Q 2023 Operating Income of $4,439 (35.5% of sales). &#160;The Operating Income decline was less than the Gross Profit decline as a result of the favorable impact in general &amp; administrative (G&amp;A) expenses of having the CooperSurgical Inc (CSI) Identifiable Intangible Asset (IIA) fully amortized in 4Q 2023. &#160;The CSI IIA amortization expense was $1,105 in 1Q 2023 (and zero in 1Q 2024). &#160;Offsetting the lower CSI IIA amortization expense in G&amp;A expenses were $342 higher litigation expenses. Combining the changes in CSI IIA amortization and litigation costs with other G&amp;A expense increases, total consolidated G&amp;A expenses were just $668 lower in 1Q 2024 than in 1Q 2023. The other components of Operating Expense, Product Development (R&amp;D) expenses and Sales &amp; Marketing (S&amp;M) expenses, were $122 and $25 higher in 1Q 2024 than in 1Q 2023, respectively. &#160;The higher R&amp;D expense was related to certification of UTMD&#8217;s own biopharma manufacturing pressure sensors. In sum, Operating Expenses were $522 lower in 1Q 2024 than in 1Q 2023. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Income Before Tax (EBT) benefitted again from higher interest income on UTMD&#8217;s cash reserves. &#160;&#160;Non-operating income in 1Q 2024, in which interest income is captured, was $915 compared to $681 in 1Q 2023. Combining the $555 lower Operating Income with $234 higher Non-operating income yielded 1Q 2024 EBT just $321 (6.3%) lower than in 1Q 2023. &#160;In contrast to a lower GPM and Operating Income margin, UTMD&#8217;s EBT margin (EBT/sales) improved to 42.3% in 1Q 2024 compared to 40.9% in 1Q 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s consolidated income tax provision rate in 1Q 2024 was 17.6% compared to 17.7% in 1Q 2023. As a result, 1Q 2024 Net Income was 6.1% lower than in 1Q 2023. During 1Q 2024 UTMD repurchased 43,108 of its shares in the open market at an average cost of $69.37/ share. UTMD did not repurchase shares in 2023. Also, because of a lower stock price at the end of 1Q 2024, there was no dilution from outstanding employee stock options for purposes of calculating diluted Earnings per Share (EPS), compared to 8,456 in share dilution in 1Q 2023. Because of the benefit of lower time-weighted diluted shares, UTMD&#8217;s EPS in 1Q 2024 were 5.7% lower than in 1Q 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s March 31, 2024 Balance Sheet, in the absence of debt, remained strong. &#160;Ending Cash and Investments were $93.8 million on March 31, 2024 compared to $92.9 million three months earlier on December 31, 2023, despite use of $4.1 million cash during 1Q 2024 to pay for stockholder dividends and share repurchases. Stockholders&#8217; Equity remained about the same at the end of 1Q 2024 as at the end of 2023, as $4.1 million in dividends and share repurchases which reduced Stockholders&#8217; Equity offset the $4.0 million in 1Q 2024 Net Income which increased Stockholders&#8217; Equity. &#160;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2024 and the end of 1Q 2023 follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%;margin-left:-1.7pt"><tr><td valign="top" style="width:172.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">&#160;</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">3-31-24</span></p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">3-31-23</span></p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#CCEEFF;width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.263</p>
</td><td valign="top" style="background-color:#CCEEFF;width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.237</p>
</td><td valign="top" style="background-color:#CCEEFF;width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">2.1%</p>
</td></tr>
<tr><td valign="top" style="width:172.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.079</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.087</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">(0.7%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:172.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#CCEEFF;width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.652</p>
</td><td valign="top" style="background-color:#CCEEFF;width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.670</p>
</td><td valign="top" style="background-color:#CCEEFF;width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">(2.7%)</p>
</td></tr>
<tr><td valign="top" style="width:172.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.739</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.739</p>
</td><td valign="top" style="width:172.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">-</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">7</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">b)</kbd><kbd style="margin-left:24.3pt"></kbd>Revenues&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. &#160;In the U.S., Ireland, UK, Canada, Australia and New Zealand, UTMD generally accepted orders directly from and shipped directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale during both 1Q 2024 and 1Q 2023. &#160;UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Total consolidated 1Q 2024 UTMD sales were $1,180 (9.4%) lower than in 1Q 2023. Constant currency sales were $1,220 (9.7%) lower. U.S. domestic sales were 13.8% lower and OUS sales were 3.5% lower. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &#160;Worldwide sales to UTMD&#8217;s largest OEM customer, which had grown rapidly in previous years, were $1,046 lower in 1Q 2024 compared to 1Q 2023, which explains most of the sales decline.  Looking forward, the current backlog for 2Q 2024 shipments to this customer, including shipments from UTMD Ireland, is $1.7 million lower than shipments in 2Q 2023. With the absence of any new orders in 2024, worldwide sales to this customer may be another $5.4 million lower during the remainder of 2024 compared to the last three quarters of 2023. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Domestic sales in 1Q 2024 were $6,192 compared to $7,185 in 1Q 2023. &#160;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">1)</kbd><kbd style="margin-left:10.8pt"></kbd>Direct sales, representing 57% of total domestic sales, were $106 (2.9%) lower in 1Q 2024 than in 1Q 2023. &#160;This was due to $139 lower NICU device sales as a result of not yet recapturing business lost in late 2023 from continuing supply chain disruption for raw material components. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">2)</kbd><kbd style="margin-left:10.8pt"></kbd>OEM sales, representing 26% of total domestic sales, were $691 (29.9%) lower. U.S. sales to UTMD&#8217;s largest OEM customer, which had grown rapidly in previous years, were $735 lower in 1Q 2024 compared to 1Q 2023. &#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">3)</kbd><kbd style="margin-left:10.8pt"></kbd>Domestic Filshie device sales were $197 (15.6%) lower in 1Q 2024 compared to 1Q 2023. &#160;Misinformation on social media from unresolved product liability lawsuits seems to be having a negative effect. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">OUS sales in 1Q 2024 were $5,149 compared to $5,335 in 1Q 2023. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were increased $40 as a result of changes in FX rates resulting primarily from a 4.3% stronger GBP. &#160;In other words, constant currency OUS sales were $5,109, which was 4.2% lower than in 1Q 2023. &#160;The foreign currency OUS sales in 1Q 2024 were $3,487, which was 68% of OUS sales and 31% of total 1Q 2024 consolidated sales. &#160;Foreign currency OUS sales in 1Q 2023 were $3,558, which was 67% of OUS sales and 28% of total 1Q 2023 consolidated sales. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table provides USD consolidated sales amounts divided into general product categories for total worldwide sales and the subset of OUS sales. &#160;Sales to UTMD&#8217;s largest OEM customer are included in the Blood Pressure Monitoring product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">WW revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:347.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:18.7pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:47.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">%</span></p>
</td><td valign="top" style="width:18.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2023</span></p>
</td><td valign="top" style="width:47.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">%</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:347.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.7pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,025</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">9</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1,015</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td></tr>
<tr><td valign="top" style="width:347.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:18.7pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,461</p>
</td><td valign="top" style="width:47.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">48</p>
</td><td valign="top" style="width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,593</p>
</td><td valign="top" style="width:47.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">45</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:347.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.7pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,642</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">15</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,762</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">14</p>
</td></tr>
<tr><td valign="top" style="width:347.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:18.7pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">3,212</span></p>
</td><td valign="top" style="width:47.1pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">28</span></p>
</td><td valign="top" style="width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">4,150</span></p>
</td><td valign="top" style="width:47.3pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">33</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:347.2pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.7pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 11,340</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.1pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">100</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:105.85pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 12,520</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.3pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">100</span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">OUS revenues (USD) by product category:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:348.9pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:18.75pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:47.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">%</span></p>
</td><td valign="top" style="width:18.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2023</span></p>
</td><td valign="top" style="width:47.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">%</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:348.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 222</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.8pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 209</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">4</p>
</td></tr>
<tr><td valign="top" style="width:348.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Gynecology/ Electrosurgery/ Urology</p>
</td><td valign="top" style="width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,108</p>
</td><td valign="top" style="width:47.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">60</p>
</td><td valign="top" style="width:18.8pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,073</p>
</td><td valign="top" style="width:47.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">58</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:348.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">395</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.8pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">377</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">7</p>
</td></tr>
<tr><td valign="top" style="width:348.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories*</p>
</td><td valign="top" style="width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1,424</span></p>
</td><td valign="top" style="width:47.25pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">28</span></p>
</td><td valign="top" style="width:18.8pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1,676</span></p>
</td><td valign="top" style="width:47.45pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">31</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:348.9pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt">Total:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.75pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,149</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.25pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">100</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:18.8pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:104.8pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 5,335</p>
</td><td valign="top" style="background-color:#CCEEFF;width:47.45pt;padding-right:5.75pt"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">100</span></p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:37.8pt"></kbd>*includes molded components sold to OEM customers.&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">8</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">c)</kbd><kbd style="margin-left:24.3pt"></kbd>Gross Profit&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Gross Profit results from subtracting the costs of manufacturing products, including quality assurance and freight for receiving raw materials from vendors, from revenues. UTMD&#8217;s Gross Profit was $1,077 (13.7%) lower in 1Q 2024 than in 1Q 2023. &#160;Gross Profit declined more than revenues due to lower absorption of manufacturing overhead costs which were 3.6% lower when sales were 9.4% lower. &#160;Because management expects revenues to decline further during the remainder of 2024, taken together with manufacturing overhead expenses not declining, management has projected a greater percentage decline in Gross Profit for the year as a whole. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">d)</kbd><kbd style="margin-left:24.3pt"></kbd>Operating Income &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Operating Income results from subtracting Operating Expenses from Gross Profit. Operating Expenses are comprised of general and administrative (G&amp;A) expenses, sales and marketing (S&amp;M) expenses and product development (R&amp;D) expenses. &#160;Consolidated Operating Expenses were $2,882 in 1Q 2024 (25.4% of sales) compared to $3,404 in 1Q 2023 (27.2% of sales). &#160;Ignoring the portion of Operating Expenses that were litigation expenses and non-cash IIA amortization expenses, Operating Expenses in 1Q 2024 were 14.4% of consolidated sales compared to 11.2% of sales in 1Q 2023. &#160;As noted above, the main FX rate differences in 1Q 2024 compared to 1Q 2023 were a stronger GBP and a weaker AUD relative to the USD. &#160;The net FX impact on OUS Operating Expense was minor. A stronger GBP in 1Q 2024 compared to 1Q 2023 increased IIA amortization expense captured in the G&amp;A category in the UK by $21. All other OUS Operating Expenses were increased by $7. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Consolidated G&amp;A expenses were $2,205 (19.4% of sales) in 1Q 2024 compared to $2,873 (22.9% of sales) in 1Q 2023. G&amp;A expenses include litigation costs which were $751 in 1Q 2024 compared to $409 in 1Q 2023. G&amp;A expenses in 1Q 2024 included $504 (4.4% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $483 (3.9% of sales) in 1Q 2023. The increase was the result of a stronger GBP as the Femcare GBP-denominated expense was the same in both periods. The major G&amp;A expense change was the $1,105 IIA amortization expense in 1Q 2023 which was zero in 1Q 2024. That prior expense had resulted from UTMD&#8217;s purchase in 2019 of the CSI remaining U.S. exclusive Filshie intangible and distribution rights, and represented 8.8% of 1Q 2023 sales. Excluding litigation costs and non-cash Filshie-related IIA amortization expenses, G&amp;A expenses were $950 (8.4% of sales) in 1Q 2024 compared to $876 (7.0% of sales) in 1Q 2023. The change in FX rates increased 1Q 2024 OUS G&amp;A expenses by $27, comprised of increasing IIA amortization expense by $21 and all other G&amp;A expenses by $6. &#160;UTMD&#8217;s Operating Income margin (Operating Income/ sales), excluding IIA amortization and litigation expense, was 45.3% in 1Q 2024 compared to 51.4% in 1Q 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">S&amp;M expenses were $412 (3.6% of sales) in 1Q 2024 compared to $387 (3.1% of sales) in 1Q 2023. &#160;The change in FX rates increased 1Q 2024 OUS S&amp;M expenses by $1. &#160;The additional $24 increase was primarily due to increases in S&amp;M salaries and benefits for employees on board in both periods. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">R&amp;D expenses in 1Q 2024 were $266 (2.3% of sales) compared to $144 (1.1% of sales) in 1Q 2023. &#160;There were no OUS R&amp;D expenses. The $122 increase was primarily due to testing and certification of materials required for biopharma manufacturing OEM customers.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In summary, Operating Income in 1Q 2024 was $3,883 (34.2% of sales) compared to $4,439 (35.5% of sales) in 1Q 2023. &#160;The only slightly lower 1Q 2024 Operating Income margin of 34.2% compared to 35.5% in 1Q 2023 was due to lower Gross Profit and higher litigation and R&amp;D expenses being offset by the expiration of CSI IIA amortization expense. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">A summary comparison of (USD) consolidated Operating Expenses follows:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2023</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">S&amp;M Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;412</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;387</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">R&amp;D Expense</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">266</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">144</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">G&amp;A Expense:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;&#160;&#160;CSI IIA amortization</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,105</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;&#160;&#160;Femcare IIA amortization</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">504</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">483</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;&#160;&#160;Litigation Expense</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">743</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">409</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0"> &#160;&#160;&#160;&#160;All Other G&amp;A Expenses</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">957</span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">876</span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Total Operating Expenses:</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 2,882</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 3,404</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">9</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">e)</kbd><kbd style="margin-left:24.3pt"></kbd>Non-operating expense/ Non-operating income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Non-operating expense, or net Non-operating income, results from the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income, royalties received from licensing the Company&#8217;s technology and other miscellaneous income. &#160;Net Non-operating income in 1Q 2024 was $915 compared to $681 in 1Q 2023. &#160;The primary difference was due to higher average cash balances in 1Q 2024 compared to 1Q 2023 with higher interest rates, which resulted in $283 higher interest income. UTMD received $43 lower Non-operating income in 1Q 2024 from renting underutilized property in Ireland compared to 1Q 2023, and the same $5 in Non-operating income from royalties. UTMD realized a $1 loss in 1Q 2024 compared to a slight gain at the end of 1Q 2023 from remeasurement of foreign currency bank balances. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">f)</kbd><kbd style="margin-left:24.3pt"></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EBT results from adding net Non-operating income or subtracting net Non-operating expense to or from Operating Income, as applicable. Consolidated 1Q 2024 EBT was $4,798 (42.3% of sales) compared to $5,119 (40.9% of sales) in 1Q 2023. The $321 (6.3%) lower 1Q 2024 EBT compared to 1Q 2023 was the result of $555 lower Operating Income offset in part by $234 higher net Non-operating income. &#160;&#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The EBT of Utah Medical Products, Inc. in the U.S. was $2,806 in 1Q 2024 compared to $2,562 in 1Q 2023. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,640 in 1Q 2024 compared to EUR 1,962 in 1Q 2023. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (101) in 1Q 2024 compared to GBP 23 in 1Q 2023. The 1Q 2024 EBT of Utah Medical Products Canada, Inc. was CAD 66 in 1Q 2024 compared to CAD 158 in 1Q 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. &#160;Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2024 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated 1Q 2024 EBITDA&#8221;) were $5,547 compared to $6,919 in 1Q 2023. Management believes that the 1Q 2024 EBITDA operating performance represents a start in 2024 that is consistent with projections provided in its 2023 SEC 10-K Report. UTMD&#8217;s trailing last twelve-month EBITDA was $25,262. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number: &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2024</span></p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">1Q 2023</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EBT</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;4,798</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ &#160;5,119</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Depreciation Expense</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">156</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">154</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Femcare IIA Amortization Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">504</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">483</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CSI IIA Amortization Expense</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,105</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Other Non-Cash Amortization Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Stock Option Compensation Expense</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">78</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">50</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">Interest Expense</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:461.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Remeasured Foreign Currency Balances</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">1</p>
</td><td valign="top" style="width:114.55pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:461.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">UTMD non-US GAAP EBITDA:</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$  5,547</p>
</td><td valign="top" style="background-color:#CCEEFF;width:114.55pt;padding-right:5.75pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">$  6,919</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">10</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">g)</kbd><kbd style="margin-left:24.3pt"></kbd>Net Income&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net Income in 1Q 2024 of $3,956 was 6.1% lower than the Net Income of $4,214 in 1Q 2023. UTMD&#8217;s Net Income margin, Net Income divided by consolidated sales, was 34.9% in 1Q 2024 and 33.7% in 1Q 2023. The average consolidated income tax provision rates (as a % of EBT) were 17.6% in 1Q 2024 and 17.7% in 1Q 2023. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:10.8pt"></kbd>h) &#160;Earnings Per Share (EPS)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EPS are consolidated Net Income divided by the weighted average number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value).</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">EPS in 1Q 2024 at $1.093 were 5.7% lower than the $1.159 in 1Q 2023. &#160;UTMD&#8217;s smaller decline in EPS relative to Net Income was a result of 18,118 fewer diluted shares used to calculate EPS in 1Q 2024 compared to 1Q 2023. Diluted shares were 3,618,168 in 1Q 2024 compared to 3,636,286 in 1Q 2023. &#160;Outstanding shares were 3,588,336 at the end of 1Q 2024. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares for option shares exercised and for shares which were repurchased during the quarter. There was no dilution from unexercised employee options. &#160;However, the total number of outstanding unexercised employee and outside director options at March 31, 2024 was 81,995 at an average exercise price of $75.10, including shares awarded but not yet vested. This compares to 84,301 unexercised option shares at the end of 2023 at an average exercise price of $74.56/ share, including shares awarded but not vested. There were no shares added for 1Q 2024 EPS dilution from options because the average exercise price was higher than the 1Q 2024 ending share price of $71.11. &#160;The number of shares added as a dilution factor in 1Q 2023 was 8,456. No options were awarded in 1Q 2024 or 1Q 2023. During the remainder of 2023 (after 1Q 2023), 19,000 non-qualified option shares were awarded to 48 employees at an exercise price of $77.07. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Outstanding shares at the end of 1Q 2024 were 3,588,336 compared to 3,629,525 at the end of calendar year 2023 and 3,628,067 at the end of 1Q 2023. The difference in outstanding shares at the end of 1Q 2024 compared to the end of 2023 resulted from 43,108 shares repurchased in the open market and 1,919 employee options exercised during 1Q 2024. UTMD repurchased 43,108 of its shares at an average price of $69.37 during 1Q 2024. Because of a time-weighted calculation, the full antidilution impact of 1Q 2024 repurchases won&#8217;t be felt until 2Q 2024. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. There were no stock repurchases in 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD paid $1,089 ($0.300/share) in cash dividends to stockholders in 1Q 2024. UTMD paid $1,070 ($0.295/share) in cash dividends to stockholders in 1Q 2023. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s closing share price at the end of 1Q 2024 was $71.11, down 16% from the $84.22 closing price at the end of 2023. &#160;The closing share price at the end of 1Q 2023 was $94.77. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">i) </kbd><kbd style="margin-left:24.3pt"></kbd>Return on Equity (ROE)&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated Stockholders&#8217; Equity for the applicable time period. Annualized ROE (before stockholder dividends) in 1Q 2024 was 12% and in 1Q 2023 was 15%. &#160;The higher ROE in 1Q 2023 was due to 7% higher Net Income divided by 9% lower average Stockholders&#8217; Equity. Targeting a high ROE of 20% remains a key financial target for UTMD management. &#160;ROE can be increased by increasing Net Income, and/or by reducing Stockholders&#8217; Equity by paying cash dividends to stockholders or by repurchasing shares. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Liquidity and Capital Resources</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">j)</kbd><kbd style="margin-left:24.3pt"></kbd>Cash flows&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $5,276 in 1Q 2024 compared to $6,915 in 1Q 2023. &#160;Net Income provided $258 less to cash in 1Q 2024 than in 1Q 2023. &#160;Other differences in cash provided during the two periods were a $1,355 higher source of cash from reduction in inventories along with $422 and $199 higher sources of cash from increases in accounts payable and accrued expenses, respectively, offset by a $2,027 higher use of cash for accounts receivable, a $1,082 lower increase in amortization expense and a $189 greater decrease in deferred income taxes. &#160;&#160;&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">11</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0">Capital expenditures for property and equipment (PP&amp;E) netting disposal were $(5) in 1Q 2024 compared to $43 in 1Q 2023. &#160;Depreciation of PP&amp;E was $156 in 1Q 2024 compared to $155 in 1Q 2023. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Cash dividends paid to stockholders in 1Q 2024 were $1,089 compared to $1,070 in 1Q 2023. &#160;UTMD spent $2,990 in 1Q 2024 to repurchase 43,108 of its shares. No shares were repurchased in 1Q 2023. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">In 1Q 2024, UTMD received $96 and issued 1,919 shares of its stock upon the exercise of employee stock options. &#160;Option exercises in 1Q 2024 were at an average price of $50.15 per share. &#160;In comparison, 1Q 2023 UTMD received $21 and issued 300 shares of its stock upon the exercise of employee stock options. &#160;Option exercises in 1Q 2023 were at an average price of $69.83 per share.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to meet the challenges of the current economic environment in achieving operating objectives, to maintain the capability to make opportunistic investments that will provide for growth in future profits and to continue to allocate capital in a way that will maximize stockholder value over time. &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">During the remainder of 2024 the Company may utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">k)</kbd><kbd style="margin-left:24.3pt"></kbd>Assets and Liabilities&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD&#8217;s March 31, 2024 Balance Sheet, in the absence of debt, continued to be strong.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">At March 31, 2024 total consolidated assets were practically the same as at December 31, 2023, but were $7.7 million higher from a year earlier at March 31, 2023. At March 31, 2024 compared to three months earlier at the end of 2023, UTMD&#8217;s cash and investments increased $939 to $93.8 million. Compared to a year earlier at March 31, 2023, cash and investments increased $12.9 million. Inventories declined $342 from the end of 2023, and $0.7 million from a year earlier. Working capital at the end of 1Q 2024 remained about the same as at the end of 2023, but was $12.6 million higher than at March 31, 2023, primarily as a result of the increase in cash. UTMD&#8217;s strong current ratio improved to 19.6 at March 31, 2024 from 15.7 at March 31, 2023. &#160;The current ratio at the end of 2023 was 22.6. Consolidated Accounts Receivable (net of allowances) increased $201 at March 31, 2024 from the end of 2023, but declined $0.2 million compared to March 31, 2023. &#160;On a rolling sales quarter basis, the aging of receivables remained at a healthy 28.5 days at the end of 1Q 2024 compared to 24.3 days at the end of 2023, and 27.3 days at the end of March 2023. &#160;&#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Net fixed assets at March 31, 2024 compared to December 31, 2023 declined $286 from $156 in depreciation, $(5) in capital expenditures and the impact of the period-to-period foreign currency exchange (FX) rates for assets OUS. &#160;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2024 and the end of 2023 follow:</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt">&#160;</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center"><span style="border-bottom:1px solid #000000">3-31-24</span></p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">12-31-23</span></p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center"><span style="border-bottom:1px solid #000000">Change</span></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">GBP</p>
</td><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.263</p>
</td><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.274</p>
</td><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">(0.8%)</p>
</td></tr>
<tr><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">EUR</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.079</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">1.106</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">(2.4%)</p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">AUD</p>
</td><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.652</p>
</td><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.682</p>
</td><td valign="top" style="background-color:#CCEEFF;width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">(4.4%)</p>
</td></tr>
<tr><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0">CAD</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.739</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.757</p>
</td><td valign="top" style="width:78.5pt;padding-right:5.75pt"><p style="font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center">(2.5%)</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">At March 31, 2024, net Intangible Assets declined $611 to 13.3% of total consolidated assets from 13.8% on December 31, 2023, as a result of $513 in amortization and the impact of an FX rate change in the GBP. &#160;The decline in net Intangible Assets from a year earlier was $4.4 million, as the Intangible Asset associated with the purchase of CSI use of intangible and exclusive U.S. distribution rights was fully amortized in October 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">A $765 increase in current liabilities at March 31, 2024 compared to December 31, 2023 was a result of a $535 increase in accrued liabilities and a $230 increase in accounts payable. But current liabilities at March 31, 2024 were $599 lower from a year earlier. The current liability changes resulted from normal business fluctuations. Long-term liabilities at March 31, 2024 compared to December 31, 2023 declined $211 primarily as a result of a $135 reduction in the deferred tax liability for the Femcare Ltd GBP IIA to $986 from $1,121 at the end of 2023. The Femcare deferred tax liability was $1,456 at March 31, 2023, and $9,084 on the date of the 2011 acquisition.  This long-term liability will be fully amortized in March 2026. &#160;Reduction of the deferred tax liability occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare Ltd IIA. There was also a 1Q 2024 $67 decline in deferred income taxes in the U.S. and Ireland. UTMD&#8217;s total debt ratio (total liabilities/total assets) as of March 31, 2024 was 5.7% compared to 5.3% as of December 31, 2023, and 7.6% on March 31, 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">As of March 31, 2024, Stockholders&#8217; Equity (SE) increased $9.7 million compared to a year earlier at March 31, 2023 despite a reduction in SE from the $7.3 million combination of share repurchases and ($1.19/ share) in stockholder cash dividends paid during the last twelve months. &#160;During 1Q 2024, SE decreased $570 from the end of 2023 while the company paid $1,089 in dividends and repurchased $2,990 in stock, which reduced SE by $4.1 million.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">12</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">l)</kbd><kbd style="margin-left:24.3pt"></kbd>Management's Outlook&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The first quarter of 2024 results were consistent with management projections for 2024 as described in UTMD&#8217;s 2023 Form SEC 10-K. But to be clear, the projections included a progressive decline in financial results during the remainder of the year. The major projected change in 2024 financial results compared to 2023 has to do with losing UTMD&#8217;s largest biopharma pressure sensor OEM customer. We understand that they have moved their sensor manufacturing work in-house, to their own non-U.S. facility. In 1Q 2024 WW sales to this customer were $1.0 million lower than in 1Q 2023, accounting for 89% of the period-to-period quarterly revenue decline. Assuming no new orders from this customer will be received by UTMD, which is consistent with experience to date in 2024, OEM sales to this customer will be $1.7, $2.0 and $1.8 million lower in 2Q, 3Q and 4Q 2024 respectively. &#160;In addition, UTMD&#8217;s largest distributor of blood pressure monitoring medical devices in China has postponed its 4Q 2024 shipments, which were $1.2 million in 4Q 2023 revenues. &#160;In other words, the total decline projected in financial results becomes greater as the current year progresses.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Objectives for 2024 remain to</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">1)</kbd><kbd style="margin-left:-4.5pt"></kbd>exploit UTMD&#8217;s pre-qualified status to introduce a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers; &#160;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">2)</kbd><kbd style="margin-left:-4.5pt"></kbd>continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">3)</kbd><kbd style="margin-left:-4.5pt"></kbd>focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.;&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">4)</kbd><kbd style="margin-left:-4.5pt"></kbd>introduce additional products helpful to clinicians through product development; &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">5)</kbd><kbd style="margin-left:-4.5pt"></kbd>continue to achieve excellent overall financial operating performance despite a contraction in revenues; &#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">6)</kbd><kbd style="margin-left:-4.5pt"></kbd>utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued; and&#160;</p>
<p style="font:10pt Times New Roman;margin:0;margin-left:36pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">7)</kbd><kbd style="margin-left:-4.5pt"></kbd>remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies. &#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:10.8pt">m)</kbd><kbd style="margin-left:24.3pt"></kbd>Accounting Policy Changes&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">None.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><b>Forward-Looking Information</b>. &#160;&#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">13</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a11"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .9267, .9042 and .9198 EUR per USD as of March 31, 2024, December 31, 2023 and March 31, 2023, respectively. &#160;Exchange rates were .7915, .7850, and .8085 GBP per USD as of March 31, 2024, December 31, 2023 and March 31, 2023, respectively. &#160;Exchange rates were 1.5332, 1.4652 and 1.4695 AUD per USD on March 31, 2024, December 31, 2023 and March 31, 2023, respectively. &#160;Exchange rates were 1.3539, 1.3204, and 1.3532 CAD per USD on March 31, 2024, December 31, 2023, and March 31, 2023 respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur, and by optimizing global account structures through liquidity management accounts.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a12"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 4. Controls and Procedures</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin-top:5pt;margin-bottom:5pt">The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2024. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of March 31, 2024, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style="font:10pt Times New Roman;margin:0">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">14</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a13"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">PART II - OTHER INFORMATION</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a14"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 1. Legal Proceedings</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD is a party from time to time in litigation incidental to its business. Presently, except for Filshie clip product liability lawsuits in discovery, there is no litigation or threatened litigation. The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a15"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 1A. Risk Factors</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#333333">In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<a id="a16"></a><p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt"><b>Item 2.</b></kbd><kbd style="margin-left:37.8pt"></kbd><b>Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The following table details purchases by UTMD of its own securities during 1Q 2024.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center"><b>ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:288pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Period</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(a)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased (1)</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(b)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Average price paid per share (1)</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(c)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Total number of shares purchased as part of publicly announced plans or programs (1)</p>
</td><td valign="top" style="width:96.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:center">(d)</p>
<p style="font:10pt Times New Roman;margin:0;text-align:center">Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="background-color:#CCEEFF;width:288pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">01/01/24 &#8211;&#160;01/31/24</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="width:288pt"><p style="font:10pt Times New Roman;margin:0">02/01/24 &#8211;&#160;02/29/24</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">16,365</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">70.37</p>
</td><td valign="top" style="width:96.2pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="background-color:#CCEEFF;width:288pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">03/01/24 &#8211;&#160;03/31/24</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">26,743</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">68.76</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.2pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="background-color:#CCEEFF;width:96.25pt;border-bottom:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
<tr style="height:1pt"><td valign="top" style="width:288pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">43,108</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">69.37</p>
</td><td valign="top" style="width:96.2pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td><td valign="top" style="width:96.25pt;border-top:0.5pt solid #000000"><p style="font:10pt Times New Roman;margin:0;text-align:right">N/A</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><span style="font-size:8pt">1) None of the shares were purchased as part of a publicly announced plan and all were purchased on the open market.</span></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The frequency of UTMD&#8217;s open market share repurchases depends on the availability of sellers and the price of the stock. &#160;The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD&#8217;s continuing and long-term pattern of open market share repurchases since 1992.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">The purpose of UTMD&#8217;s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business<span style="color:#FF0000">. </span>UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Please see item 9) Subsequent Events in the Notes to Financial Statements for shares repurchased in April 2024.</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">15</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a17"></a><p style="font:10pt Times New Roman;margin:0"><b>Item 6. &#160;Exhibits </b></p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="bottom" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="border-bottom:1px solid #000000">Exhibit #</span></p>
</td><td valign="bottom" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000">Title of Document</span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.1</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z1.htm" style="text-decoration:none">Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">31.2</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex31z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.1</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z1.htm" style="text-decoration:none">Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">32.2</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex32z2.htm" style="text-decoration:none">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">101</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0">The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): &#160;(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders&#8217; Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:358.55pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top" style="background-color:#CCEEFF;width:113.75pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">104</p>
</td><td valign="top" style="background-color:#CCEEFF;width:358.55pt"><p style="font:10pt Times New Roman;margin:0">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
</td></tr>
</table>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">16</span></p>
<hr style="page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<p style="font:10pt Times New Roman;margin:0"><span style="color:#0000FF;border-bottom:1px solid #0000FF"><a href="#a2" style="text-decoration:none">Table of Contents</a></span></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><a id="a18"></a><p style="font:10pt Times New Roman;margin:0;text-align:center">SIGNATURES</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:28.8pt"></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd><span style="border-bottom:1px solid #000000">UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:204.2pt"></kbd>REGISTRANT&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;5/10/24 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Kevin L. Cornwell&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>CEO&#160;</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:0pt">Date: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;5/10/24 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style="margin-left:204.2pt"></kbd>By: <span style="border-bottom:1px solid #000000"> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="position:absolute;font:10pt CG Times;margin-left:55.4pt"> &#160;&#160;&#160;&#160;</kbd><kbd style="margin-left:219.1pt"></kbd>Brian L. Koopman&#160;</p>
<p style="font:10pt Times New Roman;margin:0"><kbd style="margin-left:219.1pt"></kbd>Principal Financial Officer&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:10pt CG Times;margin:0;text-align:center"><span style="font-family:Times New Roman">17</span></p>
<p style="font:10pt CG Times;margin:0">&#160;</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: May 10, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt CG Times;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: May 10, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>May 10, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 32.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>May 10, 2024</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon </I><I>request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets' xlink:label='us-gaap_ProceedsFromSaleOfProductiveAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_ProceedsFromSaleOfProductiveAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquity' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureWarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureRevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureEarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureSubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureSubsequentEventsDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Long-term lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllocatedShareBasedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allocated Share-based Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllocatedShareBasedCompensationExpense' xlink:to='lab_us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by/(used in) investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by/(used in) investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Earnings Per Share, Basic and Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work-in-process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:to='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for losses on/(recovery of) accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock Repurchased and Retired During Period, Shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finite-Lived Intangible Assets Acquired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:to='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CSI Distribution Agreement Purchase Disclosure</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, diluted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in operating assets and liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesNoncurrent' xlink:to='lab_us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements and Changes in Accounting Principles</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; Investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='lab_fil_DistributionRightsAcquisitionDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CooperSurgical Inc</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the CooperSurgical Inc, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CoopersurgicalIncMember' xlink:to='lab_fil_CoopersurgicalIncMember'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:to='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyAccrual' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard and Extended Product Warranty Accrual</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyAccrual' xlink:to='lab_us-gaap_ProductWarrantyAccrual'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2024, 3,588 shares and December 31, 2023, 3,628 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition [Axis]</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the description of Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='lab_fil_DistributionRightsAcquisitionAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:label='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:to='lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets' xlink:label='us-gaap_ProceedsFromSaleOfProductiveAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromSaleOfProductiveAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from sale of equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromSaleOfProductiveAssets' xlink:to='lab_us-gaap_ProceedsFromSaleOfProductiveAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20240331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Assets' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquity' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquity_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1' use='optional' order='15.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets' xlink:label='us-gaap_ProceedsFromSaleOfProductiveAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProceedsFromSaleOfProductiveAssets' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='22.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='26.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='28.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='30.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureWarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureRevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureEarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureSubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleOfRevenuesByProductCategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AllocatedShareBasedCompensationExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProductWarrantyAccrual' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20240331.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="utmd-20240331.xsd#idr_DisclosureSubsequentEventsDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' xlink:label='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare' use='optional' order='3.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2024 [PPXK9NDL3JZWVEAM513X]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://www.utahmed.com/20240331' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://www.utahmed.com/20240331' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:srt='http://fasb.org/srt/2024' xmlns:us-gaap='http://fasb.org/us-gaap/2024' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31' xmlns:dei='http://xbrl.sec.gov/dei/2024'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
				<link:definition>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
				<link:definition>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare" id="idr_DisclosureEarningsPerShare">
				<link:definition>000150 - Disclosure - Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventories" id="idr_DisclosureInventories">
				<link:definition>000100 - Disclosure - Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails" id="idr_DisclosureStockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve" id="idr_DisclosureWarrantyReserve">
				<link:definition>000120 - Disclosure - Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition" id="idr_DisclosureRevenueRecognition">
				<link:definition>000130 - Disclosure - Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails" id="idr_DisclosureWarrantyReserveDetails">
				<link:definition>000230 - Disclosure - Warranty Reserve (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
				<link:definition>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
				<link:definition>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation" id="idr_DisclosureStockBasedCompensation">
				<link:definition>000110 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation" id="idr_DisclosureBasisOfPresentation">
				<link:definition>000080 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
				<link:definition>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
				<link:definition>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
				<link:definition>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
				<link:definition>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents" id="idr_DisclosureSubsequentEvents">
				<link:definition>000160 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails" id="idr_DisclosureSubsequentEventsDetails">
				<link:definition>000270 - Disclosure - Subsequent Events (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd' namespace='http://fasb.org/srt/2024'/>
	<import schemaLocation='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd' namespace='http://fasb.org/us-gaap/2024'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2024/dei-2024.xsd' namespace='http://xbrl.sec.gov/dei/2024'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfRevenuesByProductCategoryTextBlock' name='ScheduleOfRevenuesByProductCategoryTextBlock'/>
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrldt:dimensionItem' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionAxis' name='DistributionRightsAcquisitionAxis'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionDomain' name='DistributionRightsAcquisitionDomain'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CoopersurgicalIncMember' name='CoopersurgicalIncMember'/>
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' name='RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006392938576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,528,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006393113936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Investments</a></td>
<td class="nump">$ 93,808<span></span>
</td>
<td class="nump">$ 92,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,591<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,240<span></span>
</td>
<td class="nump">9,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">107,149<span></span>
</td>
<td class="nump">106,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,266<span></span>
</td>
<td class="nump">10,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,638<span></span>
</td>
<td class="nump">13,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">54,029<span></span>
</td>
<td class="nump">54,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(49,641)<span></span>
</td>
<td class="num">(49,350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">4,946<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">135,441<span></span>
</td>
<td class="nump">135,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,476<span></span>
</td>
<td class="nump">3,941<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,474<span></span>
</td>
<td class="nump">4,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,699<span></span>
</td>
<td class="nump">7,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2024, 3,588 shares and December 31, 2023, 3,628 shares</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,289)<span></span>
</td>
<td class="num">(10,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">138,995<span></span>
</td>
<td class="nump">138,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">127,742<span></span>
</td>
<td class="nump">128,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 135,441<span></span>
</td>
<td class="nump">$ 135,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006392962720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006390152416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 11,340<span></span>
</td>
<td class="nump">$ 12,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,574<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,766<span></span>
</td>
<td class="nump">7,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">3,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">4,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">4,798<span></span>
</td>
<td class="nump">5,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="nump">$ 4,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding (basic)</a></td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding (diluted)</a></td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">3,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="num">$ (631)<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 3,325<span></span>
</td>
<td class="nump">$ 4,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006390450544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006393141488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="num">$ (12,039)<span></span>
</td>
<td class="nump">$ 126,006<span></span>
</td>
<td class="nump">$ 114,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="num">(11,491)<span></span>
</td>
<td class="nump">129,150<span></span>
</td>
<td class="nump">118,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="num">(10,658)<span></span>
</td>
<td class="nump">138,341<span></span>
</td>
<td class="nump">128,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,221)<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (11,289)<span></span>
</td>
<td class="nump">$ 138,995<span></span>
</td>
<td class="nump">$ 127,742<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased and Retired During Period, Shares</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006388907120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="nump">$ 4,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on/(recovery of) accounts receivable</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating Lease, Right-of-Use Asset, Amortization Expense</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and other receivables</a></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">271<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(87)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">230<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">2,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">5,276<span></span>
</td>
<td class="nump">6,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of equipment</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(2,990)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(3,983)<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(358)<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">92,868<span></span>
</td>
<td class="nump">75,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">93,808<span></span>
</td>
<td class="nump">80,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006391308240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2023. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006391908400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006480580960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at March 31, 2024 and December 31, 2023 consisted of the following:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:421.4pt" valign="top"></td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:316pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> March 31, 2024  </p>
</td><td style="width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2023</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:316pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,634</p>
</td><td style="background-color:#CCEEFF;width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:295.5pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,685</p>
</td></tr>
<tr><td style="width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:316pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,302</p>
</td><td style="width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:295.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,503</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:316pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,304</p>
</td><td style="background-color:#CCEEFF;width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,394</p>
</td></tr>
<tr><td style="width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="width:316pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,240</p>
</td><td style="width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="width:295.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,582</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006394271120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At March 31, 2024, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2024 and March 31, 2023, the Company recognized $79 and $50, respectively, in stock-based compensation cost.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006479236080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> (5) Warranty Reserve. &#160;&#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2023 or March 31, 2024. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006480840672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) &#160;1Q 2024 global revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">803</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">222</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,025</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,353</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">3,108</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,461</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,247</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">395</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,642</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,788</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,424</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">3,212</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,191</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,149</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,340</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006479189920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">CSI Distribution Agreement Purchase Disclosure</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Exclusive U.S. Filshie Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution and use of intellectual property rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) effective February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which was straight-line amortized and recognized as part of G&amp;A expenses over the 4.75 year remaining life of the CSI Agreement with Femcare ended in October 2023.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006394195392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period. &#160;Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2024 and 2023, as applicable.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"></td><td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,214</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td style="width:228.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,636</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:228.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.09</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.09</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006480810352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2024 financial statements. &#160;After March 31, 2024 through May 3, 2024, the Company made additional repurchases of 63,985 shares of its stock in the open market for $4,323, at an average price of $67.57 per share.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006392654000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006394156640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:421.4pt" valign="top"></td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:316pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> March 31, 2024  </p>
</td><td style="width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2023</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:316pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,634</p>
</td><td style="background-color:#CCEEFF;width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;width:295.5pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,685</p>
</td></tr>
<tr><td style="width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:316pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,302</p>
</td><td style="width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:295.5pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,503</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:316pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,304</p>
</td><td style="background-color:#CCEEFF;width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,394</p>
</td></tr>
<tr><td style="width:421.4pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="width:316pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,240</p>
</td><td style="width:24.85pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:19pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="width:295.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,582</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006392319680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock', window );">Schedule Of Revenues By Product Category</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="width:180pt" valign="top"></td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">803</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">222</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,025</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,353</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">3,108</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,461</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,247</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">395</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,642</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:180pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,788</span></p>
</td><td style="width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,424</span></p>
</td><td style="width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">3,212</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:180pt" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,191</p>
</td><td style="background-color:#CCEEFF;width:23.05pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,149</p>
</td><td style="background-color:#CCEEFF;width:28.1pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,340</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfRevenuesByProductCategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006394370736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"></td><td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2024</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,956</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,214</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td style="width:228.2pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">-</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,618</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,636</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:228.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.09</p>
</td><td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td></tr>
<tr style="height:11.5pt"><td style="width:535.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:228.2pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.09</p>
</td><td style="width:64.8pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:267.65pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006393853264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="nump">$ 1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">6,304<span></span>
</td>
<td class="nump">6,394<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 9,240<span></span>
</td>
<td class="nump">$ 9,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006390450176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006480655680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warranty Reserve (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006392693232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 11,340<span></span>
</td>
<td class="nump">$ 12,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">6,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 1,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006480804528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-Lived Intangible Assets Acquired</a></td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem', window );">Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System</a></td>
<td class="nump">4.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006393034144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,956<span></span>
</td>
<td class="nump">$ 4,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">3,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140006392861296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 03, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased and Retired During Period, Shares</a></td>
<td class="nump">63,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 4,323<span></span>
</td>
<td class="num">$ (2,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Accelerated Share Repurchases, Final Price Paid Per Share</a></td>
<td class="nump">$ 67.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[)%P?AW-+V>38#F=D//@,K@.IR2ZF$Z7Y#M94 &%2D&QF&9H?R4FD2DNROW
M"K),>2EID4C/5 BKCS3C!NR\!K-? +NBHD><_@FQ+7O0(0]?ET\@;N7.L=S$
M$K5ULMLZV54\YU/KU)5V?<Z@^QS]TI[)#8UA;.!;*4%LP?"_?>F[UH^N(GQ2
ML*.2.&U)G->B^R'/<WP1(\7CAQ-]'P@7:%$%";FC60ED ;B@+T-7'>K@IU5P
MW6NVOM6S^IZY/<SO#:<C[D'+/?@ =U1?UJ!4*1?L+R1=K'7 X0'&T,+?$]BW
MO(YHARWM\,.T>.^D++M1A\\@G.%H](2TP\FU1]V@;@OJ_@?HO%1280=@Q;J+
MUGT/;8?3<UKSH ?J[P_VCS4K),E@A3*K=XIZ4??TVE!\4[7%>ZZPR5;3%#^#
M(+0#[J\X5WM#=]KVP^K_ U!+ P04    " !56JI8A"I6R]@$  "$$@  &
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MI'VYD7!OY%=8J? !L4L0^!< >K!IP=/_^/*@ DZ0^SS0^@*'OMQG$W#W-'X
MX\?!4V\Z'/T->OWI\/MP.AQ,;%[;:6W:M:I\O^)K%..;FDQHCMD6U[I__N&W
MO+]L)I])V9$#FKD#FE7:NR-9GD@:TQ6VF;E;V])K517:=H,H;%TWMH?P3:$F
M])NYT!&L,(<55NY+;_Z/3#A9HP0'@LHB%=,T)@D&:8Y7/5=W,>)+L&9T2V2$
M@MD[D'65(4'2EUUA(H)@:^2'Y]S#,RD[<E8K=U:K<@]OL50:$Z2*L<W0W>KP
M8(-\8Q-M,J%]#]LYK'8EK-Z*,D'^=<)J&S\9^D$)EBGCAU'+CJN3X^I4XGI4
ML:*Y3U(O2"CGF .:-CZK*-MB)B-H\47&3DPW*OSD4TRV:)98,Z1C *QW2C:8
M(K[=@"@W(*HT8)P'^#V6M'D!-./7Z:+^S#'H27O$!3CT/AB\R5Z#6PV(3'3-
MD@$6D<!N@>\57.>=B-D%9DPF[#Z9T9L]2S,]1Q[V(UB":)-R83S@8[\2XT30
M^&===29S($$J%^[<B=WNS%0> FE'9;"F3.@YP,("+*P$.T5O8(93O" "("$8
MF6V$"EI5)O$;9C&1L4$7@"NC9(U4AM@=#@UTA@&F"'3@+XC8/\'$2Y2^R$24
M_<I! 5>QS('L74!"T(PDSF+NGY61SZ7MV!<%)_O5I-PS:X_V 15+S X>VCW1
M-%,!&CEMD?+;G<BQBP5M^Y5$UQVF6\G9E+EV*30#I^V7H9E"==_K.#H*OV!)
MOYHF'QE>(S+?9R\_<&F\D;4H%5F\69&;!%GOM,O(32'H(%&_8%'_!(WN@V&-
MWETLY)L\"0.OC,X4DI74524+-O6KZ53B8QM<N-6*S^3 L&E4%5,H<-;%@BO]
M:K*<4H$2@(I^THK/1G'0<* I!=N>@\QA086PF@I'_Z>)A2;QA;!=[NXL4JW(
M=X0F+ @2^K\U/0U'WP>3#TQ/L))W?[=8GTO;L1,*XH75Q"O;2;E7XEV7$_QK
M0]8JS*QFF[19A^5.QB;4="0I+-@55C*6 AEC/.=@P>@*<)3H7J :;6")]C)8
M4\:1L+ @/WAZ(BVG0^/SANM>\8O\VV+^D<0P"2XLH[<PI=/5!07"ZM&UG!1W
MPU%OU/] 4IQU'CV7MF,G%%P+3W'M8;P1SC<HC77,R49Z)5OH71M:KVI$H<FF
MD5'8+(SK*L@%X\)JQNT?0EQO6+S4(X#*;X8%8>4781E<"[W"*"J3B$7,E3(%
M!<,3$RUZ5UFLW#LG*F<<[_J@95J5G569B.UB;1?,@HIA-17GF9TE,UB05(;%
M!W+9)-YZ$'7*+PML8K[7=#2U04'0035!#Q8+'&OOXK=8CRE <C,&<3:RR%A1
M9EG?$]KFTK#\AL B%;0=J MR#JJGU^S-'E.O")2SM>=5#.L+5?JWD@8<#5%@
MCJA1LQS*%J&PTW*$25 0:E!-J'T-5,AI]H6DJ8H.Z7E)L81:\RZPS*NPTS)\
M;(JU0R]TS*W!P0OD:F;=H\5JF*C$:7)E%'0\ Z<IUO$BWX6SH-6@FE8U3CW_
MS#=,.54./AE:_1[LU'N8P#(P>F5&M0E!5_X5C!I4#Y6GH0LL2<S:Q62J6]9R
MFX&N$ME!;AR<ZJPP>]&'71SHP6QW]I$_S0_4>OH8J?3\JW_5WQV+%6IVIW0/
MB,EPYR#!"ZG2NVQ+5&QW\+6[$72MSXYF5 BZTI=+C.:8*0'Y_8)2L;]1/Y ?
M/W;_ U!+ P04    " !56JI8,!F$K'$#  "#!P  &    'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;(U586_;-A#]*P<-V!(@M6S9[8K,-E G&UH,&;RFZ3[3
MXMEB2Y$JCXJ3_?K=4;:J 8[1+[9(WGOW[GAWG.]]^$H58H2GVCI:9%6,S76>
M4UEAK6CD&W1\LO6A5I&789=3$U#I!*IM7HS';_):&9<MYVEO'99SWT9K'*X#
M4%O7*CROT/K](IMDQXV/9E=%V<B7\T;M\![C0[,.O,I[%FUJ=&2\@X#;1?9N
M<KV:B7TR^&QP3X-OD$@VWG^5Q0>]R,8B""V641@4_SWB#5HK1"SCVX$SZUT*
M</A]9/\CQ<ZQ;!3AC;?_&!VK1?8V XU;U=KXT>_?XR&>U\)7>DOI%_:=;5%D
M4+84?7T LX+:N.Y?/1WR, "\';\ * Z (NGN'"65MRJJY3SX/02Q9C;Y2*$F
M-(LS3B[E/@8^-8R+RY4B0^"WL Y(Z**27,WSR-1BD)<'FE5'4[Q ,X4[[V)%
M\+O3J/^/SUE2KZLXZEH59PGO5!C!='(%Q;B8G>&;]G%.$]_T!;Z_?$0Z%5<'
MFYV&24M<4Z-*7&2-)"@\8K;\^:?)F_%O9T3->E&S<^P_GOSS-!>32_A4(;1.
MM=I$U+ U3KG2* O$I,A-% DJ]8BP073 H30JL)V1MBA]T&R-7'FQ@LA$QE$,
M;6H;@NA!ZA\FXU=_@W(:M ?G(QN5MM4(REH)H<-U4R*U&UNR&8(V5%I/+8?(
M7?RM->)X\YP<MRX:MV,]3&8:RQ8[=!B8,IUC$SN10O[@4FCW$A"-)&#"87A4
M^=8R,X(,)T&5WGUI7=?]?6PG4W,42\>HOGN-JH([U*9DQ#IXS6FA*_C@RA%<
M9 ^?[FXS\ $RL;WQ=:/<<W;)?*YE>TZS#Q'8_3&#?P)G*!$_HPJ TBUPBR76
M&PS'>I^.F#\9^<8X4<_YK97C(2ERK]*1I"^YDP2>#&IX04I_X5G2[5]P7KCN
M4N:]XTPSNY-[$\%E&X(<# "7X%@@$<]L*89N?)M_.97*!(8/0O^%!E(:3Z8O
M!;Y]GI.IV/E!":E&^!9OV!VZDF^[EF+@FPC8I=ZWQ#@"?)(R ,:\HDI.>TMF
MW5?(.W)S>G2J'_/!8*PQ[-+X)TB%U\W(?K=_8=YU@_6[>?<\\4#:<5^ Q2U#
MQZ-?7V<0NI'?+:)OTIC=^,A#.WU67(@8Q(#/MYYE'A;BH']WE_\!4$L#!!0
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M]([/Q%D_';_#^S>&,JVX-""P)&AT\G$:@.[GMC>L:OVL;)2ER?/;FIXZU"Z
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M33Y^B/KAIQ.BDDY4<HK]?Z_^),EQB>?]"XB^UY<'>:%6O*#ZJ0\S<+Y<W%W
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M9].W%Q'8[J_H-MXTH3_OC*=N'Y85?:]H68'DI:'VU6_8P?AA;_X'4$L#!!0
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M):T,;ASX;=,(MU^AMKM%,DX.![>JJBD<I,MY*RJ\0_K5;AQ;Z<!2J :-5]:
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MC$"[ 'N^50J/CNOWX7E+WP!02P,$%     @ 55JJ6!)+;&*Q!   ;QT  !D
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MYAH,3GU]\%P0:!=^T:9HCT&:JA(/1KE&0"7Q.H7J:X9Q!_*2@+ST"SF1.YR
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !56JI8?CX6B^\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !5
M6JI8F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( %5:JE@.CL.:U@4  -4>   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !5
M6JI8[DW&1,,%  !/%P  &               @($:#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ 55JJ6,>%<F2A @  9 <  !@
M         ("!$Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( %5:JEB$*E;+V 0  (02   8              " @>H6  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !56JI8EQVJ_8D"   6!@
M&               @('X&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ 55JJ6+X/M#(=!@  )B0  !@              ("!MQX  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %5:JEA,L]ASXP8
M (H<   8              " @0HE  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !56JI8,!F$K'$#  "#!P  &               @($C
M+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 55JJ6%<Z
MKTR/ @  T@4  !@              ("!RB\  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( %5:JEA.-^N/70(  $@%   9
M  " @8\R  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M55JJ6*5M;KJ- @  SP4  !D              ("!(S4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !56JI84_$%ZLH#   ["   &0
M            @('G-P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( %5:JEAA;SH<K (  *8%   9              " @>@[  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 55JJ6.,?L-T+ P
MFP8  !D              ("!RSX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !56JI8-_?D_U(#  "\!P  &0              @($-
M0@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %5:JECO
M"M*;]P$  *$$   9              " @99%  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ 55JJ6!.,<1V1 @  R04  !D
M     ("!Q$<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %5:JEAV"WR>4 (  *,%   9              "
M@<E5  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 55JJ
M6.UJ= \1 @  Z@0  !D              ("!4%@  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !56JI8$DML8K$$  !O'0  &0
M        @(&86@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( %5:JEA8E#+!; (  /P$   9              " @8!?  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 55JJ6,,=V$H( P  &0D
M !D              ("!(V(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !56JI84_433\T"  "Y!P  &0              @(%B90
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %5:JE@\&U7!
M! ,  "T0   -              "  69H  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 55JJ6)>*NQS     $P(   L              ( !E6L  %]R96QS
M+RYR96QS4$L! A0#%     @ 55JJ6-[ABZ+S @  OA(   \
M ( !?FP  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %5:JEA_/=]I1P$
M -@0   :              "  9YO  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( %5:JEC:<EG8> $  +$1   3              "
M 1UQ  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     C ", ; D  ,9R
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>47</ContextCount>
  <ElementCount>131</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Warranty Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails</Role>
      <ShortName>Warranty Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="utmd-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="utmd-20240331.htm">utmd-20240331.htm</File>
    <File>utmd-20240331.xsd</File>
    <File>utmd-20240331_cal.xml</File>
    <File>utmd-20240331_def.xml</File>
    <File>utmd-20240331_lab.xml</File>
    <File>utmd-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="297">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20240331.htm": {
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "utmd-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "utmd-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 129,
   "keyCustom": 2,
   "axisStandard": 3,
   "axisCustom": 1,
   "memberStandard": 4,
   "memberCustom": 7,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 47,
   "entityCount": 1,
   "segmentCount": 11,
   "elementCount": 179,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 297,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "UsdPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "E22_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E22_StEqComps-CommonStock",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation",
     "longName": "000080 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples",
     "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureInventories",
     "longName": "000100 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation",
     "longName": "000110 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve",
     "longName": "000120 - Disclosure - Warranty Reserve",
     "shortName": "Warranty Reserve",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition",
     "longName": "000130 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure",
     "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure",
     "shortName": "CSI Distribution Agreement Purchase Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare",
     "longName": "000150 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents",
     "longName": "000160 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies",
     "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables",
     "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)",
     "shortName": "Inventories: Schedule of Inventory, Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables",
     "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables",
     "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
     "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)",
     "shortName": "Inventories: Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails",
     "longName": "000220 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails",
     "longName": "000230 - Disclosure - Warranty Reserve (Details)",
     "shortName": "Warranty Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "E24Q1",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
     "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1_ProductOrService-Obstetrics",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
     "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)",
     "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Y24Q1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails",
     "longName": "000270 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "D240401_240503",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D240401_240503",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r400"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts &amp; other receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r441",
      "r442",
      "r443",
      "r444",
      "r465",
      "r500"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total adjustments",
        "totalLabel": "Total adjustments",
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r182"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization {1}",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r147",
      "r150",
      "r392"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59",
      "r72",
      "r89",
      "r121",
      "r123",
      "r128",
      "r129",
      "r136",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r201",
      "r205",
      "r218",
      "r278",
      "r335",
      "r389",
      "r390",
      "r400",
      "r424",
      "r459",
      "r460",
      "r467"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r75",
      "r89",
      "r136",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r201",
      "r205",
      "r218",
      "r400",
      "r459",
      "r460",
      "r467"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Blood Pressure Monitoring and Accessories",
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash &amp; Investments",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r382"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at beginning of period",
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r43",
      "r88"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r43"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r441",
      "r442",
      "r444",
      "r465",
      "r499",
      "r500"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options",
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock received and retired upon exercise of stock options, shares",
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r323"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r24",
      "r323",
      "r341",
      "r500",
      "r501"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2024, 3,588 shares and December 31, 2023, 3,628 shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r280",
      "r400"
     ]
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r79",
      "r83",
      "r274",
      "r287",
      "r288"
     ]
    },
    "fil_CoopersurgicalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "CoopersurgicalIncMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CooperSurgical Inc",
        "documentation": "Represents the CooperSurgical Inc, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r238"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r440"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r279"
     ]
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit attributable to exercise of stock options",
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability - Femcare IIA",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r179",
      "r180",
      "r181",
      "r395"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "auth_ref": []
    },
    "fil_DistributionRightsAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "DistributionRightsAcquisitionAxis",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights Acquisition [Axis]",
        "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DistributionRightsAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "DistributionRightsAcquisitionDomain",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Rights Acquisition",
        "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "fil_DomesticUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "DomesticUsMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DomesticUsMember",
        "documentation": "Represents the DomesticUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per common share (basic)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r120",
      "r196",
      "r199",
      "r216",
      "r217",
      "r275",
      "r289",
      "r386"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, diluted",
        "verboseLabel": "Earnings per common share (diluted)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r113",
      "r114",
      "r115",
      "r116",
      "r120",
      "r196",
      "r199",
      "r216",
      "r217",
      "r275",
      "r289",
      "r386"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r117",
      "r118",
      "r119"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r64",
      "r80",
      "r81",
      "r82",
      "r90",
      "r91",
      "r92",
      "r96",
      "r103",
      "r105",
      "r107",
      "r122",
      "r137",
      "r140",
      "r153",
      "r172",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r215",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r233",
      "r286",
      "r298",
      "r299",
      "r300",
      "r311",
      "r360"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r143",
      "r149",
      "r392"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r149",
      "r242",
      "r392"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r144",
      "r273",
      "r390",
      "r391",
      "r399",
      "r400",
      "r453",
      "r454"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r37",
      "r58",
      "r89",
      "r136",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r218",
      "r388",
      "r389",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r459"
     ]
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gynecology/Electrosurgery/Urology",
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r55",
      "r58",
      "r276",
      "r284",
      "r388",
      "r389",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r106",
      "r107",
      "r121",
      "r126",
      "r129",
      "r186",
      "r187",
      "r190",
      "r290",
      "r396"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r438",
      "r462",
      "r463"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {1}",
        "negatedLabel": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSI Distribution Agreement Purchase Disclosure",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r377",
      "r378"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r455",
      "r456"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories {2}",
        "terseLabel": "Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r384"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r383",
      "r400"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r89",
      "r136",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r202",
      "r205",
      "r206",
      "r218",
      "r322",
      "r387",
      "r424",
      "r459",
      "r467",
      "r468"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r54",
      "r282",
      "r400",
      "r439",
      "r452",
      "r466"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r68",
      "r89",
      "r136",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r202",
      "r205",
      "r206",
      "r218",
      "r400",
      "r459",
      "r467",
      "r468"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "fil_NeonatalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "NeonatalMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neonatal",
        "documentation": "Represents the Neonatal, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by/(used in) investing activities",
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r46"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements and Changes in Accounting Principles",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65",
      "r93",
      "r94",
      "r97",
      "r98",
      "r108",
      "r109",
      "r134",
      "r138",
      "r139",
      "r194",
      "r195",
      "r197",
      "r199",
      "r212",
      "r214",
      "r232",
      "r234",
      "r235",
      "r239",
      "r240",
      "r241",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "fil_ObstetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "ObstetricsMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obstetrics",
        "documentation": "Represents the Obstetrics, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income",
        "totalLabel": "Operating income",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r388",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r51",
      "r306",
      "r307"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r400"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r286"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r219",
      "r226"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "fil_OutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "OutsideUsMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutsideUsMember",
        "documentation": "Represents the OutsideUsMember, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock - options",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of equipment",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r238",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r380",
      "r393",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r457",
      "r458",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r158",
      "r161",
      "r162"
     ]
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyDisclosureTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureWarrantyReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranty Reserve",
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r238",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r380",
      "r393",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r457",
      "r458",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r76",
      "r78",
      "r86",
      "r89",
      "r95",
      "r103",
      "r106",
      "r107",
      "r136",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r196",
      "r199",
      "r200",
      "r203",
      "r204",
      "r217",
      "r218",
      "r276",
      "r285",
      "r310",
      "r343",
      "r358",
      "r359",
      "r397",
      "r398",
      "r423",
      "r435",
      "r459"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r231",
      "r277",
      "r283",
      "r400"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for losses on/(recovery of) accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r141"
     ]
    },
    "fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System",
        "documentation": "Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r378",
      "r389",
      "r469"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r49",
      "r281",
      "r301",
      "r305",
      "r309",
      "r324",
      "r400"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r90",
      "r91",
      "r92",
      "r96",
      "r103",
      "r105",
      "r107",
      "r137",
      "r140",
      "r153",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r207",
      "r209",
      "r210",
      "r213",
      "r215",
      "r228",
      "r229",
      "r298",
      "r300",
      "r311",
      "r500"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r121",
      "r124",
      "r125",
      "r127",
      "r129",
      "r130",
      "r131",
      "r133",
      "r173",
      "r174",
      "r238"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r379",
      "r385"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r30",
      "r31",
      "r32"
     ]
    },
    "fil_ScheduleOfRevenuesByProductCategoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.utahmed.com/20240331",
     "localname": "ScheduleOfRevenuesByProductCategoryTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenues By Product Category",
        "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r313",
      "r314",
      "r315",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r381",
      "r394",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r412",
      "r417",
      "r461",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r24",
      "r27",
      "r28",
      "r64",
      "r80",
      "r81",
      "r82",
      "r90",
      "r91",
      "r92",
      "r96",
      "r103",
      "r105",
      "r107",
      "r122",
      "r137",
      "r140",
      "r153",
      "r172",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r215",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r233",
      "r286",
      "r298",
      "r299",
      "r300",
      "r311",
      "r360"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r313",
      "r314",
      "r315",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r381",
      "r394",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r412",
      "r417",
      "r461",
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r122",
      "r229",
      "r238",
      "r308",
      "r312",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r418"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20240331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r122",
      "r135",
      "r229",
      "r238",
      "r308",
      "r312",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r418"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r23",
      "r24",
      "r49",
      "r177"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r24",
      "r27",
      "r28",
      "r49"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option compensation expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Common stock purchased and retired, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r23",
      "r24",
      "r49"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEventsDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock purchased and retired",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r23",
      "r24",
      "r49"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r27",
      "r28",
      "r47",
      "r325",
      "r341",
      "r361",
      "r362",
      "r400",
      "r424",
      "r439",
      "r452",
      "r466",
      "r500"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237"
     ]
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive effect of stock options",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted shares",
        "verboseLabel": "Shares outstanding (diluted)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r116"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.utahmed.com/20240331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20240331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares, basic",
        "verboseLabel": "Shares outstanding (basic)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r116"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481138/505-30-25-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001811884-24-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001811884-24-000015-xbrl.zip
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M]%__4I>EVF>;.$QG$]PC,?@F\Z@GZ%-L 4,H@!OV'!?Q9YC4%:6HE"/;C'K
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MS*Q'([6TWVR?B@^/,=NP-KE87Y@Q9=>6.49='Q_Z0W-&[:D-VV>6WP4 Z[C
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M^AK>I61DH<C^"Y5]&N( !0%MBB(B*(H9:.2(3+3_89T1<:AI<P7T(J*9<BV
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MS9EB UV0'Z>J/R<6>]! <]"00"=RWK@SF_TYU29XU3RQV:U=&_?TS;V<MP8
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MA<H^67& PM74M'B>!5Y!6:[91RK XI5MO %S&4N;*Z 7$<V4WW]I [=/]SY
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M4DUVMB\>.4$EP[1XZ9.JLM8:EQGE)KHTVY+])$ +![I;IZ8#I 6V[$O-SD+
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MA@0X;<R0ZNH>B8K7FE+92KCNH?O%A@DEV@'S@+R,VWC'J%$C9U*E6%UVCM9
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MB4-_8)4M\YF)@@!8>VG%ZOVF;;,ND_!]/KB>$8 =\/\?T2B2DF=@:5A8+M
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M2(FB:)]22;Q+ X.9GIZ>?OZ:TA8>GAFHY=U]'F&)"9:3,W%DU,.CD3"D3M,
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MUP&;2:9C9$XB 3O\B\&L^_P+B_I=I(1V6E=J0*G<V63C#MX;_'C3E0!S(F"
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M!)6$7P 1/B-"42(7;G54SD0CEXSVU0A0**.O5!\/#_?5!U"(]PI5<;"WKRJ
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MIJG*I0N\#'WGH9!ZQT5F[-4ODMGL_1RJ>$@$U+\H!U7ZY9O_ E!+ P04
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M4?F!X",3OE&;O*P53B!1(S[6K1&_YG#A@5B,*'>@8_W\Q<8);+HN#U#A/KB
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MRQ0B^YJ=$&5%V.D"'50AD Y&D+$>/1[(O#1>=9<8['="F(QPTT4YK$*4/E&
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M=I?<8MIKLF\E9YB](><NH15.675KLD*]W7[(:&;Q7=;<,0W!+4R9<AO+(*S
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M#6'D$*/GR.A+^]KVD6JJM]Z+*_+7#Y]5WY#_(R=M_,-G_PM02P,$%     @
M55JJ6,$N6GA-&   THD! !4   !U=&UD+3(P,C0P,S,Q7W!R92YX;6SM76US
MVSB2_CSS*W2Y#[ZK&L=QLK,[24UF2Y;ME&\<6V<[D]F]NDK1)"1A0Q$:@)2M
M^?4+@*3$MP9!B2(!QU4SL2TUP.[G 9IH  W\_/?'N3]8(LHP"=X?'+]\=3!
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MUHU+'!M+E&<H%/(=9Y'EGVUT2EE>U>?\LO9"*X[L-95:>C+N&",J#\2OC[;
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M)M@U0T#KW.(^Q#Z=Y#[<X;?D^/;CXIK,3AIS^*IQ3<F<U/\N&A-\*L#K+6Y
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M_R]02P$"% ,4    " !56JI8B_BCA"2&   MJ 4 $0              @ $
M    =71M9"TR,#(T,#,S,2YH=&U02P$"% ,4    " !56JI8H2(39(P(  #$
M1@  $0              @ %3A@  =71M9"TR,#(T,#,S,2YX<V102P$"% ,4
M    " !56JI8Y?)W%:P)  #S>P  %0              @ $.CP  =71M9"TR
M,#(T,#,S,5]C86PN>&UL4$L! A0#%     @ 55JJ6'?%8-*3"0  I7(  !4
M             ( ![9@  '5T;60M,C R-# S,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( %5:JEB*O:G-8R<  !'K 0 5              "  ;.B  !U=&UD+3(P
M,C0P,S,Q7VQA8BYX;6Q02P$"% ,4    " !56JI8P2Y:>$T8  #2B0$ %0
M            @ %)R@  =71M9"TR,#(T,#,S,5]P<F4N>&UL4$L! A0#%
M  @ 55JJ6/YS+S;Q!@  FQL   \              ( !R>(  '5T;61?97@S
M,7HQ+FAT;5!+ 0(4 Q0    ( %5:JEC"I%;)[@8  %L;   /
M  "  >?I  !U=&UD7V5X,S%Z,BYH=&U02P$"% ,4    " !56JI8!G+\P3@$
M  #X"P  #P              @ $"\0  =71M9%]E>#,R>C$N:'1M4$L! A0#
M%     @ 55JJ6&\>#48W!    @P   \              ( !9_4  '5T;61?
@97@S,GHR+FAT;5!+!08     "@ * 'X"  #+^0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>utmd-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:fil="http://www.utahmed.com/20240331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20240331.xsd" xlink:type="simple"/>
    <context id="Y24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="E24Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="I240509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="E23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Y23Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="E22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E23Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="E23_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E23_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E24Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="E23Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Y24Q1_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D240401_240503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="Y24Q1" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="Y24Q1" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="Y24Q1" id="fact3">Yes</dei:EntityCurrentReportingStatus>
    <dei:AmendmentFlag contextRef="Y24Q1" id="fact4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="Y24Q1" id="fact5">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="Y24Q1" id="fact6">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="Y24Q1" id="ixv-4094">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="Y24Q1" id="ixv-4095">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="Y24Q1" id="ixv-4096">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="Y24Q1" id="ixv-4097">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="Y24Q1" id="ixv-4098">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="Y24Q1" id="ixv-4099">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="Y24Q1" id="ixv-4100">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="Y24Q1" id="ixv-4101">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="Y24Q1" id="ixv-4102">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="Y24Q1" id="ixv-4103">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="Y24Q1" id="ixv-4104">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="Y24Q1" id="ixv-4105">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="Y24Q1" id="ixv-4106">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="Y24Q1" id="ixv-4107">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="Y24Q1" id="ixv-4108">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="Y24Q1" id="ixv-4109">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="Y24Q1" id="ixv-4110">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="Y24Q1" id="ixv-4111">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="Y24Q1" id="ixv-4112">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="Y24Q1" id="ixv-4113">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="Y24Q1" id="ixv-4114">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="Y24Q1" id="ixv-4115">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I240509"
      decimals="INF"
      id="ixv-4116"
      unitRef="Shares">3528426</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4117"
      unitRef="USD">93808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E23" decimals="-3" id="ixv-4118" unitRef="USD">92868000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4119"
      unitRef="USD">3591000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E23" decimals="-3" id="ixv-4120" unitRef="USD">3391000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4121"
      unitRef="USD">9240000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E23" decimals="-3" id="ixv-4122" unitRef="USD">9582000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4123"
      unitRef="USD">510000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E23" decimals="-3" id="ixv-4124" unitRef="USD">428000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4125"
      unitRef="USD">107149000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E23" decimals="-3" id="ixv-4126" unitRef="USD">106269000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4127"
      unitRef="USD">10266000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E23" decimals="-3" id="ixv-4128" unitRef="USD">10551000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4129"
      unitRef="USD">13638000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E23" decimals="-3" id="ixv-4130" unitRef="USD">13692000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4131"
      unitRef="USD">54029000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E23" decimals="-3" id="ixv-4132" unitRef="USD">54296000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4133"
      unitRef="USD">49641000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E23" decimals="-3" id="ixv-4134" unitRef="USD">49350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4135"
      unitRef="USD">4388000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E23" decimals="-3" id="ixv-4136" unitRef="USD">4946000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4137"
      unitRef="USD">135441000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E23" decimals="-3" id="ixv-4138" unitRef="USD">135458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4139"
      unitRef="USD">998000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E23" decimals="-3" id="ixv-4140" unitRef="USD">769000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4141"
      unitRef="USD">4476000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E23" decimals="-3" id="ixv-4142" unitRef="USD">3941000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4143"
      unitRef="USD">5474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E23" decimals="-3" id="ixv-4144" unitRef="USD">4710000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4145"
      unitRef="USD">986000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E23" decimals="-3" id="ixv-4146" unitRef="USD">1120000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4147"
      unitRef="USD">698000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E23" decimals="-3" id="ixv-4148" unitRef="USD">698000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4149"
      unitRef="USD">285000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E23" decimals="-3" id="ixv-4150" unitRef="USD">295000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4151"
      unitRef="USD">256000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E23" decimals="-3" id="ixv-4152" unitRef="USD">322000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4153"
      unitRef="USD">7699000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E23" decimals="-3" id="ixv-4154" unitRef="USD">7145000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E24Q1"
      decimals="INF"
      id="ixv-4155"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="E23"
      decimals="INF"
      id="ixv-4156"
      unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4157"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="E23"
      decimals="-3"
      id="ixv-4158"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4159"
      unitRef="Shares">3588000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4160"
      unitRef="Shares">3588000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="E23"
      decimals="-3"
      id="ixv-4161"
      unitRef="Shares">3628000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="E23"
      decimals="-3"
      id="ixv-4162"
      unitRef="Shares">3628000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4163"
      unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E23" decimals="-3" id="ixv-4164" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4165"
      unitRef="USD">-11289000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E23" decimals="-3" id="ixv-4166" unitRef="USD">-10658000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4167"
      unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E23" decimals="-3" id="ixv-4168" unitRef="USD">594000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4169"
      unitRef="USD">138995000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E23" decimals="-3" id="ixv-4170" unitRef="USD">138341000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4171"
      unitRef="USD">127742000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E23" decimals="-3" id="ixv-4172" unitRef="USD">128313000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4173"
      unitRef="USD">135441000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E23" decimals="-3" id="ixv-4174" unitRef="USD">135458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4175"
      unitRef="USD">11340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4176"
      unitRef="USD">12520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4177"
      unitRef="USD">4574000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4178"
      unitRef="USD">4677000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4179"
      unitRef="USD">6766000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4180"
      unitRef="USD">7843000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4181"
      unitRef="USD">2617000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4182"
      unitRef="USD">3260000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4183"
      unitRef="USD">266000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4184"
      unitRef="USD">144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4185"
      unitRef="USD">2883000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4186"
      unitRef="USD">3404000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4187"
      unitRef="USD">3883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4188"
      unitRef="USD">4439000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4189"
      unitRef="USD">915000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4190"
      unitRef="USD">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4191"
      unitRef="USD">4798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4192"
      unitRef="USD">5119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4193"
      unitRef="USD">842000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4194"
      unitRef="USD">905000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4195"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4196"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4197"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y23Q1"
      decimals="INF"
      id="ixv-4198"
      unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4199"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y23Q1"
      decimals="INF"
      id="ixv-4200"
      unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4201"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4202"
      unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4203"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4204"
      unitRef="Shares">3636000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4205"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y23Q1"
      decimals="INF"
      id="ixv-4206"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4207"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="Y23Q1"
      decimals="INF"
      id="ixv-4208"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4209"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4210"
      unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4211"
      unitRef="USD">3325000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4212"
      unitRef="USD">4763000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4213"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4214"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4215"
      unitRef="USD">156000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4216"
      unitRef="USD">155000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4217"
      unitRef="USD">513000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4218"
      unitRef="USD">1596000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4219"
      unitRef="USD">-8000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4220"
      unitRef="USD">1000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4221"
      unitRef="USD">14000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4222"
      unitRef="USD">13000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4223"
      unitRef="USD">-192000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4224"
      unitRef="USD">-3000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4225"
      unitRef="USD">79000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4226"
      unitRef="USD">50000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4227"
      unitRef="USD">9000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4228"
      unitRef="USD">2000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4229"
      unitRef="USD">214000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4230"
      unitRef="USD">-1789000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4231"
      unitRef="USD">-271000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4232"
      unitRef="USD">1084000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4233"
      unitRef="USD">87000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4234"
      unitRef="USD">-25000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4235"
      unitRef="USD">230000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4236"
      unitRef="USD">-193000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4237"
      unitRef="USD">549000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4238"
      unitRef="USD">350000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4239"
      unitRef="USD">1320000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4240"
      unitRef="USD">2701000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4241"
      unitRef="USD">5276000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4242"
      unitRef="USD">6915000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4243"
      unitRef="USD">22000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4244"
      unitRef="USD">43000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4245"
      unitRef="USD">27000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4246"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4247"
      unitRef="USD">5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4248"
      unitRef="USD">-43000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4249"
      unitRef="USD">96000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4250"
      unitRef="USD">21000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4251"
      unitRef="USD">2990000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4252"
      unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4253"
      unitRef="USD">1089000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4254"
      unitRef="USD">1070000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4255"
      unitRef="USD">-3983000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4256"
      unitRef="USD">-1049000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4257"
      unitRef="USD">-358000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4258"
      unitRef="USD">37000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4259"
      unitRef="USD">940000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4260"
      unitRef="USD">5860000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23" decimals="-3" id="ixv-4261" unitRef="USD">92868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E22" decimals="-3" id="ixv-4262" unitRef="USD">75052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4263"
      unitRef="USD">93808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="E23Q1"
      decimals="-3"
      id="ixv-4264"
      unitRef="USD">80912000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4265"
      unitRef="USD">105000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4266"
      unitRef="USD">129000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaid
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4267"
      unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4268"
      unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:SharesOutstanding
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4269"
      unitRef="Shares">3630000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E23_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4270"
      unitRef="USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4271"
      unitRef="USD">593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4272"
      unitRef="USD">-10658000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4273"
      unitRef="USD">138341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E23" decimals="-3" id="ixv-4274" unitRef="USD">128313000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4275"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4276"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4277"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4278"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4279"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4280"
      unitRef="USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4281"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4282"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4283"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4284"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4285"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4286"
      unitRef="USD">79000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4287"
      unitRef="Shares">-43000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4288"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4289"
      unitRef="USD">-769000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4290"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4291"
      unitRef="USD">-2221000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4292"
      unitRef="USD">-2990000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4293"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4294"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4295"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4296"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4297"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4298"
      unitRef="USD">-631000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4299"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4300"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4301"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4302"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4303"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4304"
      unitRef="USD">1081000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4305"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4306"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4307"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4308"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4309"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4310"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4311"
      unitRef="Shares">3588000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E24Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4312"
      unitRef="USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E24Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4313"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E24Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4314"
      unitRef="USD">-11289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E24Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4315"
      unitRef="USD">138995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4316"
      unitRef="USD">127742000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4317"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4318"
      unitRef="USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4319"
      unitRef="USD">251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4320"
      unitRef="USD">-12039000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4321"
      unitRef="USD">126006000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E22" decimals="-3" id="ixv-4322" unitRef="USD">114254000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4323"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4324"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4325"
      unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4326"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4327"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4328"
      unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4329"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4330"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4331"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4332"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4333"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4334"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4335"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4336"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4337"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4338"
      unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4339"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4340"
      unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4341"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4342"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4343"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4344"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4345"
      unitRef="USD">1070000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4346"
      unitRef="USD">1070000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4347"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4348"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4349"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4350"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4351"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4352"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4353"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-CommonStock"
      decimals="-3"
      id="ixv-4354"
      unitRef="USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      id="ixv-4355"
      unitRef="USD">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-ComprIncome"
      decimals="-3"
      id="ixv-4356"
      unitRef="USD">-11491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      id="ixv-4357"
      unitRef="USD">129150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1"
      decimals="-3"
      id="ixv-4358"
      unitRef="USD">118018000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Y24Q1" id="ixv-2223">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2023. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="Y24Q1" id="ixv-2226">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Y24Q1" id="ixv-2229">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="Y24Q1" id="ixv-2232">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;(3) Inventories at March 31, 2024 and December 31, 2023 consisted of the following:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:421.4pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:316pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; March 31, 2024  &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:316pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,634&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:295.5pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,685&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:316pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,302&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:295.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,503&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:316pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,304&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,394&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:316pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,240&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:295.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,582&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Y24Q1" id="ixv-2234">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:421.4pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:316pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; March 31, 2024  &lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:316pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,634&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:295.5pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,685&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:316pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,302&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:295.5pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,503&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:316pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,304&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:295.5pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,394&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:421.4pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:316pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,240&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:24.85pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:19pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:295.5pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,582&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4359"
      unitRef="USD">1634000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E23" decimals="-3" id="ixv-4360" unitRef="USD">1685000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4361"
      unitRef="USD">1302000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E23" decimals="-3" id="ixv-4362" unitRef="USD">1503000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4363"
      unitRef="USD">6304000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E23" decimals="-3" id="ixv-4364" unitRef="USD">6394000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="E24Q1"
      decimals="-3"
      id="ixv-4365"
      unitRef="USD">9240000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E23" decimals="-3" id="ixv-4366" unitRef="USD">9582000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Y24Q1" id="ixv-2301">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(4) Stock-Based Compensation. At March 31, 2024, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2024 and March 31, 2023, the Company recognized $79 and $50, respectively, in stock-based compensation cost.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4367"
      unitRef="USD">79000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4368"
      unitRef="USD">50000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="Y24Q1" id="ixv-2305">&lt;p style="font:10pt Times New Roman;margin:0"&gt; (5) Warranty Reserve. &#160;&#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2023 or March 31, 2024. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="E23" decimals="INF" id="ixv-4369" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="E24Q1"
      decimals="INF"
      id="ixv-4370"
      unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Y24Q1" id="ixv-2309">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) &#160;1Q 2024 global revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;803&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;222&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,025&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,353&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;3,108&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,461&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,247&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;395&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,642&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,788&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,424&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;3,212&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,191&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,149&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,340&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleOfRevenuesByProductCategoryTextBlock contextRef="Y24Q1" id="ixv-2311">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;803&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;222&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,025&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,353&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;3,108&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,461&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,247&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;395&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,642&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:180pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,788&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,424&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;3,212&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:180pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,191&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,149&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,340&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</fil:ScheduleOfRevenuesByProductCategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-4371"
      unitRef="USD">803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-4372"
      unitRef="USD">222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-Obstetrics"
      decimals="-3"
      id="ixv-4373"
      unitRef="USD">1025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-4374"
      unitRef="USD">2353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-4375"
      unitRef="USD">3108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      id="ixv-4376"
      unitRef="USD">5461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-4377"
      unitRef="USD">1247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-4378"
      unitRef="USD">395000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-Neonatal"
      decimals="-3"
      id="ixv-4379"
      unitRef="USD">1642000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-4380"
      unitRef="USD">1788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-4381"
      unitRef="USD">1424000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      id="ixv-4382"
      unitRef="USD">3212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_StGeo-DomesticUs"
      decimals="-3"
      id="ixv-4383"
      unitRef="USD">6191000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1_StGeo-OutsideUs"
      decimals="-3"
      id="ixv-4384"
      unitRef="USD">5149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4385"
      unitRef="USD">11340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Y24Q1" id="ixv-2462">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Exclusive U.S. Filshie Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution and use of intellectual property rights for the Filshie&#xae; Clip System from CooperSurgical, Inc. (CSI) effective February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which was straight-line amortized and recognized as part of G&amp;amp;A expenses over the 4.75 year remaining life of the CSI Agreement with Femcare ended in October 2023.&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="-3"
      id="ixv-4386"
      unitRef="USD">21000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="INF"
      id="ixv-4387"
      unitRef="Pure">4.75</fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem>
    <us-gaap:EarningsPerShareTextBlock contextRef="Y24Q1" id="ixv-2465">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Earnings Per Share. Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period. &#160;Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2024 and 2023, as applicable.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;March 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,956&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,214&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,636&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Y24Q1" id="ixv-2468">&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:560.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;March 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,956&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,214&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;-&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,618&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,636&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="width:535.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:228.2pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.09&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:64.8pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:267.65pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4388"
      unitRef="USD">3956000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4389"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4390"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4391"
      unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4392"
      unitRef="Shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4393"
      unitRef="Shares">8000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y24Q1"
      decimals="-3"
      id="ixv-4394"
      unitRef="Shares">3618000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Y23Q1"
      decimals="-3"
      id="ixv-4395"
      unitRef="Shares">3636000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4396"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Y23Q1"
      decimals="INF"
      id="ixv-4397"
      unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y24Q1"
      decimals="INF"
      id="ixv-4398"
      unitRef="UsdPerShare">1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Y23Q1"
      decimals="INF"
      id="ixv-4399"
      unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="Y24Q1" id="ixv-2586">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2024 financial statements. &#160;After March 31, 2024 through May 3, 2024, the Company made additional repurchases of 63,985 shares of its stock in the open market for $4,323, at an average price of $67.57 per share.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D240401_240503"
      decimals="INF"
      id="ixv-4400"
      unitRef="Shares">63985</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D240401_240503"
      decimals="-3"
      id="ixv-4401"
      unitRef="USD">4323000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="D240401_240503"
      decimals="INF"
      id="ixv-4402"
      unitRef="UsdPerShare">67.57</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
